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Abstract 
Screening for precursor adenomatous polyps has been proven to be 
effective in reducing colorectal cancer mortality risk.  Although most screening 
guidelines do not recommend any one of the several screening tests for CRC 
over the others, colonoscopy increasingly is being adopted as the primary test for 
screening.  In addition, colonoscopy is recommended for post-polypectomy and 
post-colectomy surveillance of colorectal cancer.  Despite the considerable 
evidence supporting the effectiveness of screening for CRC, its uptake has 
lagged considerably behind that of breast cancer screening.  Over the past 
twenty years, the Department of Health and Human Services (DHHS), the 
Centers for Disease Control and Prevention (CDC) and many national, state and 
local organizations have embarked on several programs and campaigns in a bid 
to raise awareness about colorectal cancer and increase screening uptake.  At 
the same time, there is a growing concern that the current physician supply is 
inadequate to support a broader colonoscopy-based screening and surveillance.  
This research examines these concerns from three fronts.  First, we use a 
population-based state-transition Markov model of the natural history of 
colorectal cancer, applied to census data and prevailing screening guidelines, to 
forecast the demand for colonoscopy and examine the impact of premature post-
polypectomy CRC surveillance on the annual volume of colonoscopies.  Second, 
we combine the Behavioral Risk Factor Surveillance System (BRFSS) survey 
with physician resource data to examine the conditional effect of county-level 
physician supply on screening participation.  Third, we use longitudinal BRFSS 
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survey data to estimate the effect of the policy of state-mandated colorectal 
cancer screening benefit by health insurers on the probability of an insured 
individual undergoing screening. 
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Chapter 1: Specific Aims 
Colorectal cancer (CRC) is the second leading cause of cancer death 
among cancers that affect both men and women in the United States with an 
estimated 51,000 deaths and 143,000 new cases in 20131.  The generally 
accepted theory of the natural history of colorectal neoplasms propounds that 
adenomatous polyps are precursors to colorectal cancer1,2.  A logical implication 
of this theory is that a clinical intervention that removes adenomatous polyps 
should impede the development of colorectal cancer in an individual. Over the 
course of the last 25 years, there has been ample evidence that screening for 
colorectal cancer and precursor adenomatous polyps can reduce mortality and 
incidence3–9.  Subsequent to empirical demonstration of the effectiveness of fecal 
occult blood screening in reducing colorectal cancer mortality through a 
randomized trial10, there have been many screening guidelines issued by various 
professional societies and the United States Preventive Services Task Force 
(USPSTF)11–15.  More recently there have been efforts to consolidate these 
guidelines by the issuing of joint guidelines16–19.  While the details may have 
some variation, most colorectal screening guidelines recommend that average-
risk individuals should be screened at regular intervals starting from age 50 years 
with one or a combination of the several screening tests available (Appendix 1).  
These include high-sensitivity fecal occult blood tests (FOBT), sigmoidoscopy 
and colonoscopy.  Stool tests such as FOBTs and fecal immunochemical tests 
(FITs) generally are considered cancer detecting in contrast to more invasive 
tests such sigmoidoscopy and colonoscopy, which are considered cancer 
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preventing.  Over time, the x-ray-based double-contrast barium enema test has 
fallen out of favor because of its low sensitivity.  Meanwhile there are newer tests 
such as stool DNA and computed tomographic colonography (also referred to as 
virtual colonoscopy) that are not recommended by the USPSTF. 
Of all the CRC screening tests currently in use, colonoscopy plays a 
pivotal role in colorectal cancer screening.  Aside from its emergence as the most 
used primary screening test, positive or inconclusive results from any other tests 
typically have to be confirmed through a colonoscopy, which then allows for a 
subsequent polypectomy, if necessary.  Colonoscopy also is recommended for 
the surveillance of individuals whose initial test revealed abnormal polyps.  Most 
guidelines recommended a surveillance frequency of five years for low-risk (less 
than 1 cm) adenomas and three years for high risk (greater than 1 cm or 3 to 10) 
adenomas17,18.  The emergence of colonoscopy as the primary CRC screening 
test presents several challenges because it is a procedure typically performed by 
gastroenterologists or general surgeons20.  It is still an open question whether 
there is enough physician capacity to meet the demand for CRC screening if 
everyone adhered to current recommendations.  The access problems that may 
be posed by capacity constraints would be made worse if physicians offered 
premature post-polypectomy CRC surveillance.  CRC surveillance is deemed 
premature if the timing of the test is earlier than what is recommended by clinical 
guidelines18,21.  The capacity question aside, there also is the issue of geographic 
disparities in the availability of gastroenterologists and general surgeons, which 
may have implications for screening participation.  A third concern that arises 
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from a colonoscopy-favored screening program is the relatively prohibitive cost of 
colonoscopy compared to other screening modalities.  As part of attempts to 
address the potential barrier posed by the relatively high cost of colonoscopy, 
several states passed laws that mandated health insurance companies to offer 
coverage of colorectal cancer screening.  This dissertation examines the 
aforementioned issues through the following specific aims: 
SPECIFIC AIMS 
1. Forecast the demand for colonoscopy and examine the impact of premature 
post-polypectomy CRC surveillance on the annual volume of colonoscopies 
2. Examine the association between CRC screening status and county-level 
primary care physician (PCP) and gastroenterologist (GI) supply. 
3. Estimate the effect of state-mandated CRC coverage on the probability of an 
insured individual undergoing CRC screening.   
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Chapter 2: Statement of purpose and background 
Over the past twenty years, the Department of Health and Human 
Services (DHHS), the Centers for Disease Control and Prevention (CDC) and 
many national, state and local organizations have embarked on several 
programs and campaigns in a bid to raise awareness about colorectal cancer 
and increase screening uptake22–25.   Research suggest that CRC screening is a 
significant contributor to the decline of CRC mortality and incidence observed 
over the past two to three decades26–28.  However, despite the considerable 
evidence supporting the effectiveness of screening for CRC, its uptake has 
lagged behind that of breast cancer screening (Appendix 2).  The DHHS in its 
midcourse review of Healthy People 2010 noted that while the overall CRC 
screening rates have increased in the last few years, the elimination of disparities 
remains a challenge29.  In addition, there are wide variations in screening rates 
geographically, both at the state and at the county level (Figure 1). 
None of the several CRC screening guidelines recommends one 
screening test over another and yet there has been an exponential increase in 
the use of colonoscopy mirroring a decrease in the use of other tests and FOBT 
particularly. Because colonoscopy is a common pathway for diagnosis and 
surveillance after polypectomy or resection and predominantly performed by 
gastroenterologists, its emergence as the de facto primary screening test of 
choice has implications on access.  With an aging population and physician 
workforce, there is some concern that the demand for colonoscopies will likely 
outstrip capacity in the near future, barring any corrective measures30,31. 
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Two of the key issues in the effort to increase CRC screening are (1) 
whether there is adequate capacity in the health system to accommodate higher 
screening rates31–35; and (2) understanding the causes of differential screening 
rates at several demographic levels34.  The three papers in this dissertation 
attempt to inform the discussion about CRC screening uptake by investigating (1) 
the magnitude of the annual colonoscopy volume required under current 
screening guidelines, (2) the effect of county-level physician supply on screening 
test use, and (3) whether state-mandated CRC screening test coverage by 
healthcare insurers had any effect on screening rates. 
SCREENING CAPACITY AND OVER-SCREENING 
The first paper addresses the question of screening capacity by estimating 
the annual volume of colonoscopies that will be produced if screening 
recommendations are followed nominally or aggressively.  There are very few 
estimates of the national capacity for colonoscopies 20,31,36.  Brown et al.20 used a 
nationally representative survey of physicians, general surgeons and 
gastroenterologists conducted between November 1999 and April 2000 to 
estimate the number of sigmoidoscopies and colonoscopies that were performed 
in the United States. Based on the reported average volume and the number of 
practicing physicians in the United States, Brown et al. estimated that 5 million 
sigmoidoscopies and 4 million colonoscopies were performed in 2000 of which at 
least 1.6 million of the colonoscopies were for screening or surveillance. 
Vijan et al.31 used data from the Clinical Outcomes Research Initiative 
(CORI) database to calculate the average number of colonoscopies performed 
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per month by gastroenterologists who reported to the CORI database.  Similar to 
the approach by Brown et al., they applied this average to the number of 
gastroenterologists in the United States to estimate the number of colonoscopies 
performed.  They then marked the number up by 33% to account for 
colonoscopies performed by physicians and general surgeons.  Vijan et al. 
estimated that 3.7 million colonoscopies were performed in 2003 of which 1.69 
million were screening-related.  It must be noted that while CORI includes a 
broad cross-section of practice types and provides a general description of 
patterns of colonoscopy utilization, the gastroenterologists who report to CORI do 
not constitute a nationally representative sample. 
Based on a survey of a nationally representative sample of practices that 
perform lower endoscopic procedures, Seeff et al.36 estimated that 2.8 million 
sigmoidoscopies and 14.2 million colonoscopies were performed in the United 
States in 2002.  Unlike the approach taken by the two studies described above, 
Seeff et al. used the total number of procedures for a practice site rather than per 
individual in their estimate.  The 17 million combined sigmoidoscopy and 
colonoscopy procedures for 2002 estimated by Seeff et al. represented an 89% 
increase over the Brown et al. estimate for 2000.  While part of this increase is no 
doubt attributable to methodological differences, several studies have reported 
significant increases in the volume of screening colonoscopies since the 
introduction of Medicare coverage of screening colonoscopy for average-risk 
patients in 2001 35,37.  Recent national surveys have also indicated a general 
increase in screening uptake 38–40.  Lieberman et al.33 used data from the Clinical 
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Outcomes Research Initiative (CORI) to analyze colonoscopy utilization patterns 
between January 2000 and August 2002.  They reported that 73.5% of all 
colonoscopies were performed in 50 to 80 year old patients.  60% of 
colonoscopies in this age group were for screening, including colonoscopies 
following an abnormal initial test, or surveillance.  When these percentages were 
applied to the Seeff et al. estimate we arrived at 6.26 million annual screening or 
surveillance-related colonoscopies among those 50 to 80 years old. 
Several changes have occurred since the few available estimates on CRC 
screening capacity were conducted.  One of the most significant changes is a 
dramatic rise in colonoscopy use.  We use a Markov decision model to estimate 
the annual volume of colonoscopies required at various levels of screening rates. 
We also examine the impact of reported over-surveillance practices by 
physicians. 
PHYSICIAN DISTRIBUTION AND CRC TESTS USE 
The landscape of test options has evolved significantly since the early 
years of CRC screening.  Flexible sigmoidoscopy is now rarely used while some 
newer tests have joined the list.  FOBT, which used to be the most used test, has 
dropped to less than 20% and colonoscopy now represents over 75% of all 
screening tests (Figure 2).  While the overall uptake of CRC screening has seen 
a steady increase over the last decade, disparities have persisted.  Several 
studies have consistently found disparities associated with age, education, 
income and access to primary care.  The disparities in up-to-date colorectal 
cancer screening have been found to exhibit significant geographic variation41.  
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Disparities aside, there are significant geographic differences in screening rates.  
There continue to be several programs aimed at improving screening among 
various target populations42.  While these targeted interventions may be an 
important part of an overall strategy, it is crucial to understand the potential 
structural and systemic issues that make it difficult for specific subpopulations to 
access CRC screening.  The effects of socio-economic status (SES) and the 
afore-mentioned individual-level risk factors that affect screening uptake have 
been examined extensively40,43–46. In contrast, the effect of systemic variation in 
physician availability has not received much attention.   
Physician recommendation has been shown to be one of the major 
determinants CRC screening 47–52 but little work has been done to investigate the 
effect of the geographic distribution of physicians on area screening rates53–55.  
Two recent studies found that racial disparities in colorectal cancer screening 
may be attributable to geographic differences in physician availability when the 
usual SES risk factors were controlled for53,55.  Soneji et al. used fixed-effect 
multivariate logistic regression to model the probability of receiving a FOBT 
within the past year or endoscopic screening within the past 5 years as a function 
of individual-level socio-economic factors and state-level physician supply55. 
They found that a disparity in the likelihood of recent CRC screening between 
whites and Hispanics became statistically indistinguishable after accounting for 
the interaction between race and state-level physician supply.  Benarroch-
Gampel et al. found from the analysis of Texas Medicare claims data that greater 
area availability of colonoscopists and PCPs is associated with increased use of 
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colonoscopy in whites but decreased use in minorities53.  They defined 
colonsocopists as gastroenterologists and surgeons, family practitioners and 
other specialists who performed 5 or more colonoscopies per year. 
The effects of access to healthcare on health outcomes have been well 
documented.  In contrast, we wanted to estimate the effect of physician 
availability on the probability of undergoing screening, independent of socio-
economic confounders.  Our approach attempts to elicit the effect of geographic 
variation in PCPs and gastroenterologists supply on CRC screening rates at the 
county level.  With colonoscopy becoming the de facto gold standard test and 
comprising over three quarters of all screening tests, it is acutely important to 
understand the barriers and predictors. 
LEGISLATIVE MANDATES AND CRC SCREENING TEST USE 
As part of the efforts to increase access to CRC screening the United 
States congress and several states have passed mandates binding insurers to 
cover CRC screening56,57.  Congress mandated coverage of CRC screening for 
high-risk Medicare beneficiaries in 1998.  The mandate was expanded to cover 
average-risk Medicare beneficiaries in 2001.  Beginning in 1999, a patchwork of 
legislations and voluntary agreements in several states to induce health insurers 
to cover CRC screening has evolved, culminating in the Affordable Care Act58 
mandate which required all health plans post September 23, 2010 to cover 
colorectal cancer screening tests.  These laws and agreements vary in the extent 
of mandated CRC screening benefits. Even though CRC screening guidelines 
issued by both the American Cancer Society and then U.S. Agency for Health 
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Care Policy and Research in 1997 included FOBT, sigmoidoscopy and 
colonoscopy59, a survey of health plans in 1999-2000 found that 43% did not 
cover colonoscopy60. This observation led some to argue that the passage of 
state insurance coverage mandates was largely part of a barrage of legislation to 
regulate health insurers in the aftermath of the so-called HMO backlash 12,61.  
Health Insurance Coverage Mandates 
The argument for mandating coverage of specific services or conditions is 
predicated on the unique nature of the health insurance.  According to 
Summers62, the standard competitive equilibrium theory would indicate that 
health insurers and the insured will negotiate to a point where the marginal cost 
of providing the health benefit is equal to the value the insured places on the 
benefit.  However, there is often mitigating factors that make it impossible to 
arrive at this ideal equilibrium.  These factors include imperfect information 
between the insurer and the insured, and society’s willingness to provide charity 
care for the uninsured when they become ill and lack the ability to bear the cost 
of care.  The existence of imperfect information during the transactional process 
between the insurer and insured regarding the prevalence of a specific condition 
can lead to the undesirable consequence of adverse selection into the insurance 
pool.  Because the provision of relatively low-cost preventive care can avert the 
use of future expensive therapeutic care, it would be reasonable to assume that 
providers of health insurance would be willing to offer coverage for those 
services.  However, with the considerable churn in membership experienced by 
health plans in recent years, there may not be enough incentive to provide 
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coverage for preventive care because of the likelihood that the benefit of the 
averted catastrophic event may accrue to another insurer.  The aforementioned 
argument would suggest that mandating CRC screening coverage is good policy. 
On the other hand, one of the fundamental arguments against mandates is 
overutilization of covered services.  In the case of CRC screening coverage, it 
may lead to more frequent rescreening than would have been the case in the 
absence of a coverage mandate.  There is some evidence of such overuse of 
colonoscopy.  Another argument against mandates is that it increases the overall 
cost of providing health insurance and therefore prices out some firms or 
individuals63.  Thus, while a mandate would make a specific benefit available to 
an insured individual, the society as a whole may suffer as a result of fewer 
people being insured.  Moreover, health insurance coverage mandates could 
have wage-depressing effects as firms may overcome the constraint posed by 
the upward shift of the cost of providing insurance by reducing wages62,64–66.  
Mandates have also been shown to have a regressive effect.  A recent study 
found that while Medicare coverage of colonoscopies for CRC screening 
increased the overall use by 3.5 percentage points. However, because those with 
higher levels of income and education had exhibited a greater increase in CRC 
test use, the authors suggest that coverage mandates, (ultimately financed by 
collective premiums), indirectly transfer resources from those disadvantaged to 
those who have access67,68. 
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CRC Coverage Mandates 
Between 1998 and 2010 several states passed laws or arranged 
agreements with health insurance organizations to offer coverage for CRC 
screening.  Early adopters of CRC coverage included California, Illinois, 
Minnesota and Missouri.  These mandates and agreements had varying scopes.  
Some states required a complete coverage of CRC screening based on the CRC 
screening guidelines from the American Cancer Society while others were not 
explicit on the extent of coverage.  By 2010, 35 states, including the District of 
Columbia that had some form of mandated CRC screening coverage.  For the 
purposes of our study, we included only states that have CRC coverage 
mandates that are backed by law and are specific in the coverage benefits.  
Previous studies of the effect of mandated health insurance benefits have mostly 
demonstrated minor effects on the desired health behavior outcomes 69,70.  Very 
few studies have examined the effect of mandates on public health screening 
participation and in particular the effects of CRC screening mandates on 
screening participation in the United States71.  Consistent with similar studies on 
mandated health benefits for other diseases, the effect of CRC screening 
mandates on screening participation is inconclusive.  We used a large national 
survey to assess the effect of state level legislation of screening rates. 
CONTRIBUTION OF DISSERTATION TO PREVIOUS WORK 
This research aims to inform two critical questions that were part of the 
National Institutes of Health (NIH) state-of-the science conference convened in 
201034: 1) What factors influence the use of CRC screening, and 2) What are the 
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current and projected capacities to deliver CRC screening at a population level? 
The first paper in this dissertation attempts to estimate the volume of screening 
colonoscopies that will be generated under various scenarios of physician 
response to surveillance guidelines.  We examine whether screening coverage 
mandates are useful tools for increasing screening participations.   
Some have argued that the fight to eradicate health disparities needs to 
focus on policies that address systemic inequitable access to healthcare in 
addition to individual characteristics72.  The second and third papers in this 
dissertation examine the impact of forces outside of the individual’s locus of 
control on their CRC screening usage. We look at the effect geographic variation 
in physician supply has on access to CRC screening status and also attempt to 
quantify the effect of state-mandated health insurance coverage of CRC 
screening.  
 
 
  
14 
 
Figure 1: Proportion of eligible adults who reported receipt of adequate FOBT or 
endoscopic testing in 2012* 
 
 
*Source data: Behavioral Risk Factors Surveillance System (BRFSS), 2012 survey 
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Figure 2: Percentage of adults aged 50 years and older who ever had a colorectal 
endoscopy or FOBT: 1987 – 2005 
 
Source data: Centers for Disease Control and Prevention, National Center for Health Statistics. 
National Health Interview Survey 
Figure 3: United States population growth relative to 2010 baseline 
 
Source data: United States Census Bureau 
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Chapter 3: The impact of early aggressive surveillance for colorectal 
cancer 
INTRODUCTION 
Colonoscopy is the common diagnostic pathway for all primary screening 
tests for colorectal cancer (CRC).  Although most screening guidelines do not 
recommend any one of the several screening tests for CRC over the others, 
colonoscopy increasingly is being adopted as the primary test for screening 
33,35,73.  In addition, colonoscopy is recommended for post-polypectomy and post-
colectomy surveillance of CRC.  The National Cancer Institute’s Cancer Trends 
Progress Report 2009/2010 Update 74 reported that between 2000 and 2008, 
while the national uptake of fecal occult blood test (FOBT) for CRC screening 
decreased, use of colonoscopy rose exponentially in the same period.  Efforts 
over the last decade to raise the awareness of the benefits of CRC screening,75 
as well as increased accessibility (e.g., Medicare coverage since 2001 76) to 
colonoscopy, are expected to cause overall screening rates, and uptake of 
colonoscopy in particular, to continue to rise.  Additionally, the volumes of 
inpatient and outpatient colorectal procedures are forecasted to grow by 40.6 and 
21.3 percent, respectively, as a result of the ageing of the US population 30 
(Figure 3).  All CRC screening tests impose a downstream demand for 
colonoscopies through diagnostic testing and surveillance.  Concerns therefore 
have been raised about the adequacy of the current capacity in the health care 
system to meet continuing growing demand for colonoscopies resulting from a 
higher screening uptake over time coupled with a shift towards the use of 
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colonoscopy as the primary screening test 20,31,32,77.  The conclusions from the 
few studies on the capacity for endoscopic screening have been mixed 20,32,36.  
Two of the studies found that the current endoscopic capacity in the United 
States is inadequate to meet screening requirements if CRC screening rate 
among the eligible population reached 70% 20,31.  One other study concluded that 
providing a one-time screen endoscopic screening for the unscreened population 
could take up to 10 years 32.  Moreover, these studies predated the marked shift 
towards the use of colonoscopy as the screening test of choice. 
The limitations of the existing studies on endoscopic capacity aside, 
recent evidence of aggressive or premature post-polypectomy CRC surveillance 
suggests that we need to reexamine the demand for colorectal colonoscopy with 
respect to the physician capacity to provide it 78–81.  Surveillance colonoscopy is 
recommended for patients who undergo surgical resection of Stage I, II, or III 
colon and rectal cancers or curative-intent resection of Stage IV cancers 82.  A 
survey of gastroenterologists and surgeons found that 24% of gastroenterologists 
recommend surveillance of a hyperplastic polyp, contrary to many of the existing 
guidelines 80.  A recent national survey of primary care physicians in open-access 
systems found that 61% of the respondents would recommend surveillance of a 
hyperplastic polyp in five years or less 83.  The study also found that 71% of the 
physicians would recommend surveillance of a single tubular adenoma in three 
years or less.  Hyperplastic polyps are benign nonneoplastic lesions and are 
found in 10% of persons who are screened.  Current guidelines recommend that 
patients presenting hyperplastic polyps undergo screening every 10 years, while 
18 
 
those with one or two tubular adenomas undergo screening in 5-10 
years18,19,21,84.  Both of the above surveys also reported that gastroenterologists, 
surgeons and primary care physicians often recommended surveillance in 
excess of guidelines.  With surveillance accounting for 36.5% of all 
colonoscopies among 50 to 80 year old patients 33, premature surveillance can 
have a significant impact on the annual volume for colonoscopies.  In this study, 
we use CRC screening uptake and census data together with a Markov 
simulation model to forecast the demand for colonoscopy and examine the 
impact of premature post-polypectomy CRC surveillance on the annual volume of 
colonoscopies. 
METHODS 
Markov model of the natural history of CRC 
We used a state-transition Markov model to simulate the natural history of 
CRC based on the adenoma-carcinoma sequence 1,2.  The model included the 
following health states: disease-free, precancerous adenomatous polyps (low-
risk, defined as < 1cm or high-risk, defined as ≥ 1cm), preclinical cancer (local, 
regional or distant), clinical cancer (local, regional or distant), and death (Figure 
4).  At the start of the simulation, a cohort of 50-year old persons with an average 
risk of CRC enters the model and progress annually through various states until 
death.  A person may die from CRC-related causes or from other causes as 
determined by age-specific mortality rates.  We modeled annual transitions 
through the various health states based on probabilities estimated through 
calibrations to polyp prevalence and cancer incidence from epidemiologic data.  
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We calibrated our natural history model to data from the Survival, Epidemiology, 
and End Results Program (SEER) from the early 1970s85 under the assumption 
that CRC screening was low at that time and therefore the effect of screening on 
CRC observed incidence was not significant.  Figures 5 and 6 show that age-
specific and stage-specific CRC incidence rates produced by our model matched 
epidemiologic data from SEER. 
Data 
Key parameter estimates used in the model are included in Table 1. 
Parameter estimates for the natural history model were obtained from screening 
and autopsy studies available in the literature.  Estimates of CRC prevalence and 
mortality were obtained from SEER data.  We applied age-specific population 
estimates from the current census projections of the United States population to 
calculate the final number of annual colonoscopies. 
Screening and surveillance 
We superimposed on the natural history model a screening mechanism 
that either could identify and remove adenomas or identify, stage, and treat CRC.  
The screening strategies we considered included annual FOBT, flexible 
sigmoidoscopy (FS) every 5 years, FOBT/FS combined and colonoscopy every 
10 years for average-risk persons 50 years or older18,19,84.  Persons who tested 
positive with FOBT, FS or the combination test received a follow-up colonoscopy.  
Polyps found during colonoscopy were removed.  Persons who underwent 
polypectomy returned to a disease-free state; however, their transition probability 
to a low-risk polyp state was higher than that of disease-free persons who did not 
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have a history of adenomatous polyp, and also depended on whether their 
previously diagnosed polyp was of low or high risk.  The probability of developing 
a low-risk polyp from a disease-free state increased 2-fold for those with a history 
of low-risk polyps and 4-fold for those with a history of high-risk polyp compared 
to those with no polyp history.  Persons with a history of high-risk polyp 
underwent surveillance every three years while those with a history of low-risk 
polyp had a surveillance schedule of every five years in accordance with 
surveillance guidelines18,86.  Persons who were screened positive with CRC were 
moved to a “detected cancer” state.  Survival for persons with either detected or 
undetected CRC was based on SEER relative survival data.  For each screening 
or surveillance encounter, we modeled the fatal risk associated with 
colonoscopy.  
Estimating the number of colonoscopies performed annually  
For any particular screening strategy, we simulated a cohort of average-
risk 50-year olds to estimate the expected number of colonoscopies an individual 
would undergo each year, as well as life-years gained relative to no screening.  
The stopping age for screening was 75 years, and 80 years in the case of those 
undergoing surveillance.  The cohort-specific results were extrapolated to the US 
population aged 50 years and older by using age-specific census population 
data.  For the population eligible to be screened, we ran the model for each age-
group starting at age 50 years and obtained the number of colonoscopies 
generated annually by the cohort until they no longer were within the screening 
and surveillance recommendations.  For example, to estimate the number of 
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colonoscopies performed on those aged 50 - 80 years in 2010, we ran the model 
for 30 cohorts of 50-year-old persons from 1980 through 2010. Persons who 
were 50 years old in the 1980 will be 80 years old at iteration 30 of the 
simulation, coinciding with the year 2010.  The total number of colonoscopies for 
any particular calendar year was calculated by summing the number of 
colonoscopies performed for all ages.  We then adjusted the results to reflect the 
uptake rate of CRC screening.  To obtain the total number of colonoscopies 
resulting from the use of a combination of different screening tests, we ran the 
model separately for each test and calculated a weighted sum using test type 
distribution data from the 2005 National Health Interview Survey (NHIS) on CRC 
test use38,74.   
We used US Census population projections to estimate the future volume 
of colonoscopies under the simplifying assumption that the natural history 
parameters will remain constant.  We further assumed that screening tests will 
comprise of 75% colonoscopy and 25% FOBT.  This assumption is based on the 
fact that analysis from the 2005 NHIS found that 76.4% of the screened 
population received colonoscopy, 18.1% received FOBT and 5.5% were 
screened with FS only, or in combination with FOBT38.  Screening uptake in the 
future years were extrapolated by fitting a polynomial regression to the available 
screening uptake data from 2000 through 200874. 
To examine the impact of premature post-polypectomy CRC surveillance, 
we specified that a proportion of patients with a history of adenomas undergo 
surveillance at a shorter time interval than the guidelines recommend 78–81.  
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Patients with a history of high-risk polyps were allowed to undergo early 
surveillance at one or two years, or at the recommended three years. Those with 
a history of low-risk polyps were allowed to undergo early surveillance at three or 
four years, or at the recommended five years. We calculated the number of 
CRCs and colonoscopy-related deaths that would result under each of the 
scenarios.  We examined the harms and benefits of premature surveillance by 
estimating the number of colonoscopy-related deaths as well as CRC deaths.  
First, under the recommended surveillance levels, and then under the 
assumption that 50% of the surveillance recommended at three years were done 
annually.   
RESULTS 
Current volume of colonoscopies 
Under the assumption that screening and surveillance guidelines were 
adhered to and uptake was 50%, we estimated that 6.62 million colonoscopies 
related to CRC screening and surveillance were performed in 2008 (Table 2).  
We projected that 37.4% of the total colonoscopies performed were for 
surveillance.  If 50% of the patients who were supposed to have received 
surveillance at 3 and 5-year intervals received premature surveillance at 1 and 3-
year intervals respectively, the annual volume of colonoscopies would increase 
to 7.6 million, a difference of about 1 million. 
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Projected demand for colonoscopies 
We forecasted the annual number of colonoscopies up to the year 2020 
under the assumption that screening uptake will increase gradually from the 
current 54% to 70% based on the trend from previous years. We also assumed 
that primary screening tests comprised of 25% FOBT and 75% colonoscopy.  At 
a screening uptake of 54% and without accounting for premature surveillance, 
we forecasted that 7.0 million colonoscopies would be performed in 2010 (Figure 
6).  By 2020, the volume of colonoscopies would be 11.2 million based on an 
estimated screening uptake of 71%.  We found that the number of colonoscopies 
estimated to have been performed in 200436 is approximately equal to number 
estimated by our model for 2005 under the assumption that there was 50% 
premature post-polypectomy surveillance colonoscopies. 
Impact of premature postpolypectomy surveillance 
The number of colonoscopies projected for 2010 increased by a million 
from 7.0 million to 8.3 million if 50% of patients who have had a polypectomy 
underwent premature screening at one-year instead of three-year intervals and at 
three-year instead of five-year intervals.   
We did a sensitivity analysis to estimate the volume of colonoscopies 
under different premature surveillance intervals.  We considered surveillance 
intervals of one year, three years or the recommended five years for individuals 
with history low-risk polyps.  For those with history high-risk polyps, we 
considered intervals of one year, two years or the recommended three years.  In 
all cases we assumed that 50% of surveillance colonoscopies were premature. 
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We estimated that at a screening uptake of 50%, 6.5 million colonoscopies 
were performed in 2009, not accounting for premature surveillance. However, 
this number increased by up to 70% to 11 million colonoscopies if 50% of all 
individuals who underwent polypectomy were put under annual surveillance. 
If all the eligible population were screened from 1979 through 2009 under 
the current screening guidelines, we estimated 55,625 CRC deaths and 1,268 
colonoscopy-related deaths in 2009.  If we assume that 50% of those with high-
risk adenomas were put on annual surveillance instead of the recommended 
three-year interval, we projected that CRC deaths in 2009 would have been 
reduced by 731 (1%) while colonoscopy deaths would have increased by 99 
(8%). 
DISCUSSION 
Although most screening guidelines do not specify colonoscopy as the 
preferred screening modality, its utilization has increased markedly in recent 
years.  Despite the fact that only 65% of the eligible population is currently being 
screened 87, there has been anecdotal evidence that there is colonoscopy 
shortage in some areas of the nation 88.  Ongoing campaigns to raise the 
awareness about the benefits of CRC screening, coupled with overuse of 
colonoscopy in some settings, highlight the need to understand the current 
resource requirements and capacity for colonoscopy.  In a statement released 
after the 2010 State-of-the-Science Conference on Enhancing Use and Quality of 
Colorectal Cancer Screening, the National Institutes of Health concluded that a 
better understanding is needed about “the projected demand, and the impact of 
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overuse and misuse on capacity estimates” 34.  Our analysis used current 
screening data in a simulation model to forecast the annual volume of 
colonoscopies and examined some of the impacts of overuse of colonoscopy. 
Based on current screening and surveillance guidelines we found that the 
annual volume of colonoscopies is could double between 2006 and 2020 to 
about 11.2 million. Additionally, we found that even a conservative assumption 
about premature post-polypectomy surveillance resulted in an additional 18% 
increase in the volume of colonoscopies.   
The few available estimates of the national physician capacity for 
colonoscopies reported vastly different numbers20,31,36.  Moreover, an estimate of 
the available national capacity to provide colonoscopy is only a first step.  It does 
not address the geographic distributional differences, which may be pertinent to 
the issue of disparities.  Recent national surveys have indicated a gradual 
increase in screening uptake38–40.  Concurrent to this increase in screening 
uptake is a dramatic shift towards colonoscopy as the preferred screening test. 
However, until recently, the USPSTF did not explicitly model the outcomes of 
screening guidelines89.  The impact of any particular screening schedule on the 
colonoscopy demand and supply equation is not well understood. 
Our study made an assumption that FOBT and colonoscopy were the two 
major tests for CRC.  While that assumption has largely been true in the last five 
years, the test landscape is gradually evolving. Some tests have fallen out of 
favor and newer tests are gaining acceptance.  More studies are needed to 
understand the impact these changes on the resources needed for an equitable 
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access to screening.  Also, an analysis that examines capacity at an aggregate 
level fails to account for important regional and local dynamics, which may have 
a significant impact on access.  We address the impact of geographic distribution 
of physicians in our second paper. 
STUDY LIMITATIONS 
Our study has some limitations.  We assumed that once a person started 
screening with a particular test that same test would be used throughout the 
person’s screening lifetime.  In practice, individuals may start with one screening 
test and switch to another.  Our model also assumed that all adherent individuals 
started screening at 50 years and adherence with screening and surveillance 
guidelines is perfect once a person underwent the first screening.  The impact of 
this assumption on the total number of colonoscopies was somewhat mitigated 
by adjusting the overall screening uptake rate. 
We also did not consider the role newer tests such as computed 
tomographic colonography (CTC) will play in the future of CRC screening.  There 
are several ongoing trials aimed at assessing the performance of CTC in 
detecting adenomas and the debate about the CTC as a comparable CRC 
screening tool to colonoscopy is gaining momentum.  
CONCLUSION 
Premature surveillance increases the volume of colonoscopies by as 
much as 70% with a relatively small benefit while imposing substantial risks.  The 
aging of the US population and the increased accessibility of healthcare through 
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the Affordable Care Act are expected to substantially increase the demand for 
healthcare services. This growing demand for healthcare services in not matched 
by increased production of health professionals. Etzioni et al. estimated that CRC 
procedures will grow by up to 40.6 percent by 2025.  In light of some evidence of 
insufficient access to colonoscopy and the expected increase in the population 
eligible for screening90, premature surveillance will impose a further strain on the 
limited resources.  Such a constraint may exacerbate existing disparities in CRC 
screening.  In the next paper, we investigate the association between county-
level physician supply and an individual's probability of undergoing CRC 
screening.  
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Figure 4: Health states used in modeling the natural history of colorectal cancer 
 
 
No Lesion Low risk < 
1 cm 
High risk 
≥ 1 cm 
Death  
Colorectal 
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Local 
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Regional 
Distant 
Precancerous 
 
Preclinical 
Cancer 
Clinical 
Cancer 
Death from 
colonoscopy and 
other causes 
Screening 
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Table 1: Inputs used in the Markov Model 
Variable Value, % References 
Natural history   
Prevalence of polyps at age 50 years 20.0    91–96 
  Low-risk (< 1cm) 90.5    97–99 
  High-risk (≥ 1cm) 9.5    97–99 
Prevalence of preclinical cancer at age 50 years   
  Localized 0.1    85 
  Regional 0.02   85 
  Distant 0.001  85 
Annual transition probability from   
  Normal epithelium to low-risk polyp Age-specific 91–96 
  Low-risk polyp to high-risk polyp 1.62   100–102 
  High-risk polyp to localized cancer 3.58   103 
  Localized cancer to regional cancer 28.0    85 
  Regional cancer to distant cancer 63.0    85 
Annual probability that CRC will become symptomatic  85 
  Localized cancer 25.0    85 
  Regional cancer 55.0    85 
  Distant cancer 100.0    85 
Annual CRC-specific mortality rate   
  Localized cancer 0.2    85 
  Regional cancer 3.2    85 
  Distant cancer 56.6    85 
CRC = colorectal cancer, FOBT = fecal occult blood test 
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Table 1 (Continued): Inputs used in the Markov Model 
Variable Value, % References 
Test characteristics   
  FOBT sensitivity for polyps 10.0    3,104 
  FOBT sensitivity for cancer 60.0    41,42 
  FOBT specificity 92.0    41,42 
   
  Colonoscopy sensitivity for low risk polyps 85.0    59,105 
  Colonoscopy sensitivity for high risk polyps and cancer 95.0    59,105 
  Colonoscopy specificity 100.0    59,105 
  Probability of dying from colonoscopy   0.01   59,105 
   
  Polyps and cancer reachable by sigmoidoscope 50.0    11,59 
  Sigmoidoscopy sensitivity for reachable low-risk polyps 85.0    59,105 
  Sigmoidoscopy sensitivity for reachable high-risk polyps 95.0    59,105 
  Sigmoidoscopy sensitivity for reachable cancer 95.0    59,105 
  Sigmoidoscopy specificity 100.0    59,105 
CRC = colorectal cancer, FOBT = fecal occult blood test 
 
 
 
  
31 
 
Figure 5: Stage-specific CRC incidence rates 
Figure 6: Age-specific CRC incidence rates 
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Table 2:  Estimated number of colonoscopies performed in 2008 at recommended surveillance 
and at 50% premature surveillance. (Compliance at 50%) 
 
 
Primary test 
Percent of all 
tests performed 
(%) 
Number of 
colonoscopies at 
recommended 
surveillance 
(Millions) 
Number of 
colonoscopies at 50% 
premature 
surveillanceǂ 
(Millions) 
Colonoscopy 76.4 5.58 6.34 
FOBT 18.1 0.94 1.09 
Sigmoidoscopy 4.4 0.08 0.14 
FOBT/Sig 1.1 0.02 0.04 
Total 100 6.62 7.61 
ǂ Surveillance at 1 year instead of every 3 years and at every 3 years instead of 5 years 
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Table 3: Estimated number of colonoscopy-related and cancer deaths in 2009 assuming 100% 
screening uptake over the last 30 years 
 
 
Number of 
colonoscopy-related 
deaths 
Number of cancer 
deaths 
Recommended surveillance 
 
1,268 55,625 
50% of surveillance 
recommended at 3 years is done 
annually 
1,367 54,894 
Net (% change) 99 (8%) -731 (1%) 
 
 
Figure 7: Projected annual demand for colonoscopies when primary test type 
distribution is 75% colonoscopy and 25% FOBT 
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Chapter 4: Physician Supply and CRC Screening Rates 
INTRODUCTION 
Evidence of the clinical10,106–111 and cost effectiveness89,112–115 of 
colorectal cancer (CRC) screening has accumulated since the 1990s. In spite of 
the considerable evidence as well as several campaigns supporting CRC 
screening, only 65% of the eligible population was compliant with screening in 
201287.  In addition to the relatively low screening rates, there is a lot of variation 
geographically, with rates ranging from 57% to 75% among states in 2010116. 
CRC screening is recommended by the United States Preventive Services 
Task Force (USPSTF), the U.S. Multisociety Task Force and the American 
Cancer Society (ACS) for average-risk individuals starting at age 5021,117,118.  
Recommended screening tests include annual fecal occult blood tests (FOBT), 
flexible sigmoidoscopy every 5 years, colonoscopy every 10 years, and more 
recently, computed tomographic colonoscopy.  FOBT use increased steadily 
throughout the 1990s until 2001, after which a sharp decline in use began119.  
The sharp decline in the use of FOBT coincided with a reciprocal increase in 
colonoscopy use.  The emergence of colonoscopy as the primary CRC screening 
test poses potential access problems, which are not associated with FOBT.  
Although CRC incidence and mortality have been decreasing steadily for more 
than a decade27, disparities remain among racial groups and socio-economic 
strata120–122.  Not surprisingly, disparities also exist in CRC screening test 
use40,123,124,124,125.  
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Nationally representative studies have shown that CRC screening 
participation is associated with a number of demographic characteristics, 
including health and behavioral risk factors and patient-level access to 
health23,25–29.  In smaller studies, physician recommendation of screening ranked 
high among factors associated with adherence to CRC screening43,47,51,126,127.  
While patient-level characteristics associated with CRC screening participation 
have been well examined, the effect of physician supply has not received a 
similar level of study.  Moreover, there is evidence that the supply and 
geographical distribution of physicians can impact healthcare delivery, utilization 
and outcomes128–130.  To expand our understanding of the disparities associated 
with CRC screening participation, we combine survey data and physician 
resource data to examine the conditional effect of regional physician supply on 
screening participation.   
AIM 
In this study, we examine the relationship between CRC screening rates 
and physician supply.  Specifically, we used survey data to analyze the 
association between CRC screening status and county-level primary care 
physician (PCP) and gastroenterologist (GI) supply. 
METHODS 
Data 
We used data from the 2010 Behavioral Risk Factor Surveillance System 
(BRFSS) survey to obtain individual-level screening status, county screening 
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rates and other demographic characteristics, both at the individual and county 
level.  The BRFSS is a state-level survey that measures the prevalence of major 
behavioral risks, chronic health conditions and use of preventive services among 
adults associated with premature morbidity and mortality131.  Initially launched in 
1984 with only 29 states, the BRFSS now collects data on residents nation-wide 
through annual telephone-based random digit dialing surveys. The BRFSS 
survey included questions on CRC screening participation in 1997, 1999, and 
every even year starting from 2002.  We based our analyses on the 
subpopulation of respondents aged 50 to 80 years who indicated that they had 
not been previously diagnosed with colon or rectal cancer. Although the USPSTF 
recently recommended 75 years as the cutoff age for screening of average-risk 
individuals, we used 80 years as the cutoff age because the survey questions 
elicited retrospective screening status117.  All cases with missing values were 
excluded from our analyses. 
County-level physician counts and census demographic data were 
obtained from Health Services Resource Administration’s (HRSA) Area Health 
Resource File (AHRF).  The AHRF includes data on health professions, 
socioeconomic and environmental characteristics maintained at the county 
level132.  We merged the BRFSS and physician datasets using county FIPS code 
as the common key. 
Variables 
Our main outcome variable was a respondent’s CRC screening status.  
The BRFSS survey included questions on FOBT and endoscopy use for all 
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respondents 50 years or older.  We created two binary variables that determined 
each respondent's FOBT status and endoscopy status (i.e., flexible 
sigmoidoscopy or colonoscopy). FOBT status was defined as having received a 
blood stool test in the past two years or not.  
Each respondent's FOBT status was determined from the following two questions 
on the BRFSS survey: 
 (1) A blood stool test is a test that may use a special kit at home to determine 
whether the stool contains blood.  Have you ever had this test using a home kit?; 
and 
(2) How long has it been since you had your last blood stool test using a home 
kit? 
Sigmoidoscopy or colonoscopy use was determined from the following three 
BRFSS survey questions:  
(1) Sigmoidoscopy and colonoscopy are exams in which a tube is inserted in the 
rectum to view the colon for signs of cancer or other health problems. Have you 
ever had either of these exams? 
(2) For a sigmoidoscopy, a flexible tube is inserted into the rectum to look for 
problems. A colonoscopy is similar, but uses a longer tube, and you are usually 
given medication through a needle in your arm to make you sleepy and told to 
have someone else drive you home after the test. Was your most recent exam a 
sigmoidoscopy or a colonoscopy?; and 
(3) “How long has it been since you had your last sigmoidoscopy or 
colonoscopy?”  
Endoscopy status was defined as having received either flexible sigmoidoscopy 
in the last five years or colonoscopy in the last 10 years, or not. 
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Physician Density 
The primary predictor for the analyses was the county physician per 
population ratio, which we termed physician density.  From the AHRF data, we 
calculated three physician densities, namely, GI density, GI and general surgeon 
(GS) density and PCP density.  PCPs included general family medicine, general 
practice and general internal medicine specialties.  We defined physician density 
as the number of physicians engaged inpatient care per 100,000 persons 18 
years and older.  We used the adult population as the denominator because we 
excluded pediatricians and pediatric subspecialties.  Physician densities were 
calculated for years 2001 through and 2010 and averaged.  Only physicians 
designated as active and in clinical practice in the AHRF database were included 
our analysis.  An examination of county-level physician densities revealed 
several counties with extreme values.  Also, we expected that physician 
productivity would be affected by the available capacity. To account for the non-
linear relationship between physician density and CRC screening status, we 
created categorical variables for GI, GS and PCP densities by grouping GI and 
GS into quartiles and PCP into quintiles (Appendix 3 - Appendix 6). 
 
Other variables 
Individual level characteristics such as gender, race, age, marital status, 
education and income level obtained from the BRFSS data were included in our 
models.  Based on exploratory analysis and findings from previous studies that 
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examined  factors associated with screening participation23,40–43, we included a 
set of health and risk factor predictors as well as patient-level predictors for 
health care access.  Health and risk factor predictors included self-rated health 
status, cigarette smoking, alcohol use, physical activity and body mass index.  
For patient-level health care access variables we included “having a doctor or 
usual place of care”, “having health insurance” and “time since last doctor visit” 
(Table 5).  Because educational attainment and income were strongly correlated, 
we avoided multicollinearity in our models by creating a new composite variable, 
to serve as a socio-economic status (SES) indicator.   
Statistical Analyses 
We analyzed an individual’s screening status with a series of binary and 
multinomial multiple logistic regression models.  We modeled screening with 
FOBT and screening with endoscopy independently using physician density and 
a set of demographic and other explanatory variables (Table 6).  We also 
conducted analysis on an outcome of having been screened with either FOBT or 
endoscopy.  Our exploratory analysis indicated a strong correlation between 
CRC screening participation and prostate specific antigen (PSA) test use among 
men and mammography use among women.  We therefore ran separate 
analyses for men and women in order to independently adjust for the effect of 
either test.   
CRC screening participation rates among states in the United States has a 
range of more than 18 percentage points116.  To examine whether there were 
some endogenous characteristics within states, which enabled screening 
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participation or otherwise, we analyzed the effect of physician density on the 
probability of being up-to-date with CRC screening status for states with high 
CRC screening participation rates compared to those with low participation rates. 
We therefore ran two separate models for the five states with screening rates in 
the 25th percentile and five states above the 75th percentile. 
Marginal effects were calculated for each predictor following each 
regression estimation.  All statistical analyses were performed using survey 
commands in Stata version 12 (StataCorp 2011) and the weighting scheme 
employed in the BRFSS survey data was applied. 
RESULTS 
Study Population 
Our analysis sample included the population aged 50 to 80 years who 
answered questions about CRC screening on the 2010 BRFSS survey.  The 
proportions of the eligible population that were up-to-date with FOBT, endoscopy 
and either test were 18.0% (95% CI, 17.8% - 18.3%), 61.7% (95% CI, 61.3 - 
62.0) and 66.7% (95% CI, 66.3 - 67.0 &), respectively (Table 5).  Overall, women 
were more likely than men to have undergone screening with either test: 67.3% 
(95% CI, 66.9 - 67.7%) versus 65.9% (95% CI, 65.4 - 66.5%).  Women also were 
more likely to have undergone endoscopy, with participation at 62.3% (95% CI, 
61.9 - 62.8%) compared to men, at 61.6% (95% CI, 61.0% – 62.2%).  
Conversely, more men used FOBT with participation at 18.6% (95% CI, 18.2% - 
19.0%) compared to women, at 17.5% (95% CI, 17.2% - 17.8%).  Among all 
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races, Non-Hispanic whites were the most likely to have undergone endoscopy, 
with participation at 64.9% (95% CI, 64.5-65.2%) followed by blacks, Hispanics 
and Other at 61.8%, 53.7% and 47.7%, respectively.  Among blacks, 22.2% 
(95% CI, 21.1% - 23.3%) received FOBT, more than any other race or ethnicity.  
Both FOBT and endoscopy use increased with age but at a decreasing gradient.  
Overall screening participation was least among those 50 - 54 years old at 49.9% 
(95% CI, 49.1 - 50.8%), and peaked at 77.7% (95% CI, 76.9% – 78.4%) among 
those 70 –74 years.  Current smokers were about 20% less likely to have 
undergone endoscopy than non-smokers.  Those who reported having a doctor 
or usual place of care were more than two times more likely to have undergone 
FOBT, endoscopy or either test. 
Men who underwent prostate-specific antigen (PSA) testing in the last two 
years were three times more likely to have undergone FOBT than those who did 
not (24.0% versus 7.9%).  For endoscopy, having undergone PSA testing in the 
last two years doubled the chance of being up-to-date (72.8% versus 36.6%).  
Mammography status within the last two years exhibited a similar association 
with both FOBT and endoscopy test use (Table 5).  Appendix 7 shows a positive 
monotonic relation between quartiles of county-level gastroenterologist density 
and being up-to-date with endoscopic screening.  A similar relationship was 
exhibited between county-level PCP density and being up-to-date with 
endoscopic screening (Appendix 8). 
Adjusted patterns of association between outcomes and predictor 
variables were similar to the unadjusted rates.  Blacks were significantly more 
42 
 
likely to have received FOBT than whites (4.0 increase among men; 5.2 increase 
among women).  When either test was considered, there was no significant 
difference in the adjusted probability of having undergone CRC screening 
between blacks and whites among men.  Among women, blacks were 
significantly more likely to have undergone either test compared to whites.  
Having undergone PSA test or mammography within the previous two years 
produced the largest increases of 22.2 and 27.9, respectively, in the adjusted 
probability of being screened with either FOBT or endoscopy.   
Physician Density and Screening Participation 
The categorical variable GI density was obtained by grouping the county 
GI densities of respondents into quartiles with the first quartile from 0 to 1.3, 
second quartile from 1.3 to 4.2, third quartile from 4.2 to 6.8, and the last quartile 
greater than 6.8 per 100,000 persons.  County-level PCP density was grouped 
into quintiles because the range was considerably greater than that of GI density.   
The quintiles ranged from 2 to 53.3, 53.3 to 71.3, 71.3 to 88.5, 88.5 to 113.7 and 
greater than 113.7 per 100,000 persons.  In order to adjust for the effect of PSA 
test use among men and mammography use among women, we performed 
separated analysis for each gender. 
We found a statistically significant association between county-level GI 
density and the adjusted probability of having undergone endoscopy for CRC 
screening in the past 10 years (Tables 6 and 7).  The adjusted probability of 
having undergone endoscopy within the past 10 years increased by 3.9% (95% 
CI, 1.9 - 6.0%) for men and 3.0% (95% CI, 1.3 - 4.7%) for women who resided in 
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a county with GI density greater than 6.8 per 100,000 persons compared to the 
baseline GI density of less than 1.3 per 100,000 persons.  County-level PCP 
density was a significant predictor of an individual's endoscopy status among 
men but not women.  Among men, the adjusted probability of having undergone 
endoscopy increased significantly by 2.4 (95% CI, 0.1 - 4.8) at PCP density 
greater than 113.7 per 100,000 persons. 
In the equivalent analysis with FOBT status as the predictor, we did not 
find a significant or monotonic association between either GI density or PCP 
density and the adjusted probability of being screened with FOBT among men or 
women.  However, there was a significant effect of GI density on the adjusted 
probability of having received either FOBT or endoscopy. 
States with low screening rates compared to states with high screening rates 
From our analytical sample, we obtained two subpopulations comprised of 
observations from counties from states with the highest five screening rates and 
from counties from states with the lowest five screening rates.  Only states with 
at least 10 counties were considered.  We repeated the logistic regression 
analysis separately for these two subpopulations.  In the states with the lowest 
screening rates, there was a significant association between county-level GI 
density and the adjusted probability of having undergone CRC screening with 
either test (Table 8).  We did not find a significant association between GI density 
and CRC screening status among respondents from states with the highest 
screening rates.  PCP density had no significant effect on the CRC screening 
status of respondents from the states with low screening rates.  On the other 
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hand, for the states with the highest screening rates, the adjusted probability of 
having undergone either test increased by 5.2 (95% CI, 0.2 - 10.3) for those who 
resided in counties with PCP density greater than 113.7 per 100,000 persons 
compared with the baseline. 
While the effect of GI density on CRC screening status was considerably 
different for states with the lowest screening rates versus states with the highest 
screening rates, the effects of the other covariates in our model were similar for 
the two subpopulations (Table 3). 
Is Effect of PCP density on CRC screening status moderated by GI density? 
PCPs may influence screening uptake in two ways.  First, by 
recommending screening to their patients126,133 and second, by performing 
endoscopic screening 20,36.  We therefore included interaction terms in our 
models to determine whether the effect of PCP density on endoscopic screening 
status was moderated by GI density.  We found no sizeable interaction between 
PCP density and GI density (Appendix 10).  
DISCUSSION 
Our analyses of the 2010 BRFSS data found that GI density, and to a 
lesser extent PCP density, are predictors of undergoing endoscopic CRC 
screening.  The adjusted probability of undergoing endoscopy was 3.9 
percentage points greater among male respondents of counties with GI densities 
in the fourth quartile of the distribution, compared to the first quartile.  Among 
female respondents, the increase was 3.0 percentage points.  The effect of GI 
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density on CRC screening persisted even when the outcome was either FOBT or 
endoscopy.  In addition, the association of GI density and the adjusted probability 
of undergoing endoscopic screening was more pronounced in states that had the 
lowest CRC screening rates.  The results of our analyses were consistent with 
other studies that evaluated the association between physician density and CRC 
screening and outcomes128,134.  
The adjusted probability of having been screened with FOBT showed a 
small association among male respondents who resided in counties with PCP 
density greater than 88.5 per 100,000 persons.  This result was contrary to our 
expectation and suggests that PCPs are more likely to perform endoscopy when 
the PCP to patient ratio exceeded a certain threshold.   
Our analyses suggest that the continued decline of FOBT use and the 
concomitant increase in the use of endoscopy as the primary CRC screening test 
has the potential to widen disparities if the geographic distribution of GIs is 
skewed.  However, CRC screening disparities may be mitigated by encouraging 
the use of FOBT.  For example, we found that although a lesser proportion of 
black males have undergone endoscopy, compared to whites, there was no 
significant difference in the overall screening rate. 
States with the lowest screening rates showed strong association between 
GI density and CRC screening status of respondents, but no such effect was 
found with states with the highest screening rates.  For the subgroup of states 
with the highest screening rates, we observed that a PCP density of greater than 
113.7 per 100,000 persons was associated with a 5.2 point marginal increase in 
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the probability of undergoing screening.  Although endoscopies are mainly 
performed by GIs, earlier studies indicated that a substantial number of PCPs 
performed endoscopies for CRC screening. Further work is needed to 
understand the underlining cause of the disparate effect of GI density in the two 
sub populations.  There may be some underlining geographical or policy 
differences that differentially impact CRC screening uptake.  One consideration is 
examining the effect of state-level CRC screening mandates and campaigns on 
screening participation.  In addition, the effect of physician supply on health 
outcomes may operate differently for metropolitan verses non-metropolitan 
areas.128 
Several studies have examined the physician supply required to provide 
the annual number of endoscopies that would be generated by different CRC 
screening strategies31,32,135,136.  However, these studies approached the problem 
from a national or state perspective and did not address the effects of small-area 
variation in physician supply.  While the overall physician supply is of great 
importance to delivering health care, geographic distribution may affect 
disparities in health outcomes. 
STUDY LIMITATIONS 
There are several limitations in our study. First, a respondent’s county or 
even state of residence at the time of the BRFSS survey interview may not be 
the same county where he/she resided five or ten years before.  As a result, it 
may be inaccurate to associate an endoscopy received five to ten years ago with 
a particular geographic location.  Second, the assumption that respondents 
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sought and received endoscopy in their county of residence may not be an 
accurate one.  It is possible that respondents underwent endoscopy in facilities 
outside their county of residence. Perhaps, a more accurate analytical strategy 
would be one that considers physician density within some radius of the 
respondent’s residence.  However, such analysis requires information that is 
unavailable in the BRFSS data.  Third, the BRFSS data did not allow us to 
disentangle diagnostic endoscopies from those performed solely for CRC 
screening.  The distinction is important because barriers to undergoing 
endoscopy may operate differently for diagnostic versus screening tests. Fourth, 
the BRFSS data are self-reported and may suffer from recall bias and as a result 
in inaccuracies in the reported timing of screening tests received in earlier years.  
Fifth, physician supply data sourced from the American Medical Association have 
inaccuracies because of reporting lags and self-reporting 137.  The effect of 
reporting lags was partly mitigated by our use of average counts over the period 
from 2001 to 2010.  Last, our study did not take geographic variation in physician 
practice styles into account.  Variation in physician productivity could confound 
the association between physician density and screening status. 
CONCLUSION 
Geographic variations in CRC screening may be partly attributable to 
inequalities in physician supply, particularly, GIs.  Efforts aimed at reducing 
disparities in CRC screening may need to consider, in addition to individual 
factors, the role played by physician supply and capacity. 
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Table 4: Percentage of respondents who reported undergoing CRC screening within recommended time intervals, BRFSS, 2010 
  FOBT in the past 2 years Up-to-date with endoscopya 
Up-to-date with  
FOBT or endoscopy 
Characteristic N % 95% CI N % 95% CI N % 95% CI 
Total 255521 18.0 [17.8, 18.3] 256987 61.7 [61.3, 62.0] 257473 66.7 [66.3, 67.0] 
Gender          
Female 157916 17.5 [17.2, 17.8] 159165 62.3 [61.9, 62.8] 159436 67.3 [66.9, 67.7] 
Male 97605 18.6 [18.2, 19.0] 97822 60.9 [60.3, 61.5] 98037 65.9 [65.4, 66.5] 
Age          
50 - 54 45085 11.8 [11.3, 12.3] 45180 44.9 [44.1, 45.7] 45206 49.9 [49.1, 50.8] 
55 - 59 48733 15.6 [15.1, 16.2] 48974 61.3 [60.6, 62.1] 49022 66.0 [65.3, 66.7] 
60 - 64 49453 20.3 [19.7, 21.0] 49807 66.9 [66.2, 67.6] 49880 72.2 [71.5, 72.9] 
65 -79 43437 22.6 [21.9, 23.2] 43796 71.1 [70.3, 71.8] 43893 76.3 [75.5, 77.0] 
70 - 74 35210 23.4 [22.6, 24.2] 35466 73.0 [72.2, 73.7] 35560 77.7 [76.9, 78.4] 
75 - 80 33603 23.4 [22.7, 24.2] 33764 72.6 [71.8, 73.4] 33912 77.6 [76.8, 78.3] 
Race/Ethnicity          
White 208418 18.0 [17.7, 18.2] 209989 64.0 [63.7, 64.4] 210326 68.8 [68.4, 69.1] 
Black 18884 22.2 [21.1, 23.3] 18825 61.2 [60.0, 62.5] 18894 67.1 [65.9, 68.3] 
Hispanic 13250 14.5 [13.4, 15.5] 13204 47.1 [45.5, 48.7] 13238 53.0 [51.4, 54.6] 
Other 11776 18.6 [17.2, 19.9] 11770 53.1 [51.2, 55.0] 11799 59.2 [57.3, 61.0] 
Marital status          
Unmarried 68822 16.5 [16.0, 17.0] 69109 53.0 [52.3, 53.7] 69232 58.7 [58.0, 5.94] 
Widowed 41090 20.1 [19.4, 20.7] 41286 63.0 [62.1, 63.8] 41424 68.4 [67.5, 69.2] 
Married 144834 18.3 [17.9, 18.6] 145812 64.3 [63.9, 64.7] 146035 69.0 [68.6, 69.4] 
Self-rated health status         
Excellent 38923 17.5 [16.9, 18.2] 39249 61.8 [60.9, 62.8] 39292 66.6 [65.6, 67.5] 
Very good 77988 18.2 [17.8, 18.7] 78631 64.2 [63.5, 64.8] 78742 69.2 [68.6, 69.8] 
Good 79205 17.9 [17.5, 18.4] 79669 61.5 [60.8, 62.1] 79814 66.5 [65.9, 67.1] 
Fair/Poor 58395 18.4 [17.9, 19.0] 58438 58.4 [57.7, 59.2] 58622 63.6 [62.9, 64.4] 
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Table 4. (Continued) 
  FOBT in the past 2 years Up-to-date with endoscopya 
Up-to-date with  
FOBT or endoscopy 
Characteristic N % 95% CI N % 95% CI N % 95% CI 
Having a doctor or usual place of care       
No 21400 7.9 [7.28, 8.64] 21360 27.9 [26.8, 29.1] 21386 31.8 [30.6, 33.0] 
Yes 233606 19.1 [18.8, 19.3] 235112 65.0 [64.6, 65.3] 235567 70.1 [69.7, 70.4] 
Checkup in the last 12 months        
No 56304 8.6 [8.2, 9.1] 56498 41.1 [40.3, 41.8] 56538 44.6 [43.8, 45.3] 
Yes 196944 20.8 [20.5, 21.2] 198219 67.8 [67.4, 68.1] 198656 73.2 [72.8, 73.6] 
Physical activity within the past 30 days       
No 72562 16.2 [15.8, 16.7] 72765 56.0 [55.3, 56.6] 72938 60.9 [60.2, 61.6] 
Yes 182639 18.7 [18.4, 19.0] 183899 63.8 [63.4, 64.2] 184211 68.8 [68.4, 69.2] 
Smoking status          
Non-smoker 216176 18.6 [18.3, 18.9] 217652 64.5 [64.1, 64.8] 218060 69.3 [68.9, 69.7] 
Smoker 38134 14.9 [14.3, 15.5] 38119 45.7 [44.8, 46.6] 38186 51.7 [50.7, 52.6] 
PSA within the last 2 years        
No 29138 7.9 [7.4, 8.4] 29071 36.7 [35.7, 37.7] 29102 40.1 [39.1, 41.1] 
Yes 63683 24.0 [23.4, 24.5] 63996 72.8 [72.1, 73.5] 64142 78.5 [77.8, 79.2] 
Mammography within the last 2 years       
No 33550 7.1 [6.6, 7.5] 33654 33.3 [32.4, 34.2] 33681 36.8 [35.8, 37.7] 
Yes 123310 20.2 [19.9, 20.6] 124485 69.9 [69.4, 70.3] 124719 75.3 [74.8, 75.7] 
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Table 4. (Continued) 
  FOBT in the past 2 years Up-to-date with endoscopya 
Up-to-date with  
FOBT or endoscopy 
Characteristic N % 95% CI N % 95% CI N % 95% CI 
          
GI densityb          
0 - 1.3 59550 17.0 [16.4, 17.5] 59840 58.3 [57.6, 59.1] 59948 63.3 [62.6, 64.0] 
1.30 - 4.2 57445 18.3 [17.8, 18.9] 57747 61.4 [60.7, 62.0] 57859 66.6 [65.9, 67.3] 
4.2 - 6.8 56265 19.5 [19.0, 20.1] 56696 62.2 [61.5, 63.0] 56793 67.8 [67.1, 68.6] 
> 6.8 55715 17.6 [17.1, 18.1] 56134 66.0 [65.3, 66.6] 56239 70.0 [69.4, 70.7] 
PCP densityc          
2 - 53.3 46640 17.8 [17.2, 18.4] 46878 59.7 [58.9, 60.5] 46978 64.7 [63.9, 65.5] 
53.3 - 71.3 46388 17.5 [16.9, 18.1] 46658 60.2 [59.4, 61.0] 46726 65.2 [64.4, 66.0] 
71.3 - 88.5 45889 19.3 [18.7, 20.0] 46203 61.1 [60.2, 62.0] 46296 66.6 [65.7, 67.5] 
88.5 -  113.7 46203 19.6 [19.0, 20.2] 46503 63.9 [63.0, 64.7] 46592 69.2 [68.4, 70.0] 
> 113.7 43855 17.1 [16.5, 17.6] 44175 66.5 [65.8, 67.3] 44247 70.6 [69.9, 71.3] 
 
a Up-to-date with endoscopy means flexible sigmoidoscopy in the last five years or colonoscopy in the last 10 years 
b Number of gastroenterologists engaged inpatient care per 100,000 persons 18 years and older 
c Number of primary care physicians engaged inpatient care per 100,000 persons 18 years and older 
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Table 5: Adjusted marginal changes of predicted probability of undergoing CRC screening, men, 50 - 80 years old 
  FOBT Endoscopy Either test 
Characteristic 
Marginal 
change P>z 95% CI 
Marginal 
change P>z 95% CI 
Marginal 
change P>z 95% CI 
GI density (0 - 1.3)         
1.3 - 4.2 1.3 0.053 [0.0, 2.6] 1.9 0.020 [0.3, 3.5] 2.5 0.002 [0.9, 4.0] 
4.2 - 6.8 0.9 0.204 [-0.5, 2.4] 1.8 0.049 [0.0, 3.6] 2.5 0.006 [0.7, 4.2] 
> 6.8 -0.1 0.897 [-1.8, 1.6] 3.9 0.000 [1.9, 6.0] 3.8 0.000 [1.7, 5.8] 
PCP density (2 - 53.3)         
53.3 - 71.3 -0.4 0.638 [-1.8, 1.1] -0.5 0.584 [-2.3, 1.3] -0.4 0.621 [-2.2, 1.3] 
71.3 - 88.5 1.2 0.156 [-0.4, 2.8] -0.3 0.782 [-2.2, 1.7] 0.1 0.902 [-1.8, 2.0] 
88.5 -  113.7 0.8 0.369 [-0.9, 2.5] 1.8 0.079 [-0.2, 3.8] 1.3 0.185 [-0.6, 3.3] 
>113.7 -1.3 0.183 [-3.1, 0.6] 2.4 0.038 [0.1, 4.8] 1.7 0.145 [-0.6, 4.0] 
Age (0 - 54)          
55 - 59 3.0 0.000 [1.6, 4.4] 14.2 0.000 [12.4, 16.0] 13.0 0.000 [11.3, 14.8] 
60 - 64 7.5 0.000 [6.1, 9.0] 15.5 0.000 [13.7, 17.4] 15.5 0.000 [13.7, 17.3] 
65 -79 7.6 0.000 [6.1, 9.1] 18.4 0.000 [16.4, 20.3] 18.0 0.000 [16.1, 19.9] 
70 - 74 7.9 0.000 [6.3, 9.6] 20.1 0.000 [18.1, 22.1] 18.5 0.000 [16.5, 20.5] 
75 - 80 8.4 0.000 [6.6, 10.1] 21.3 0.000 [19.2, 23.4] 20.1 0.000 [18.1, 22.1] 
Race (White)          
Black 4.0 0.000 [2.0, 6.0] -1.3 0.248 [-3.4, 0.9] -0.7 0.531 [-2.8, 1.4] 
Hispanic -0.6 0.610 [-3.0, 1.8] -7.8 0.000 [-10.8, -4.9] -6.4 0.000 [-9.2, -3.6] 
Other 2.8 0.026 [0.3, 5.3] -6.1 0.000 [-9.1, -3.2] -4.4 0.003 [-7.2, -1.5] 
Marital status (Unmarried)         
Widowed -1.7 0.09 [-3.6, 0.3] -3.1 0.012 [-5.6, -0.7] -3.1 0.010 [-5.5, -0.7] 
Married -0.8 0.174 [-2.0, 0.4] 3.0 0.000 [1.6, 4.3] 1.9 0.005 [0.6, 3.2] 
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Table 5. (Continued) 
  FOBT Endoscopy Either test 
Characteristic 
Marginal 
change P>z 95% CI 
Marginal 
change P>z 95% CI 
Marginal 
change P>z 95% CI 
SES          
1 1.9 0.118 [-0.5, 4.2] 5.9 0.000 [2.9, 8.8] 5.5 0.000 [2.6, 8.4] 
2 1.3 0.205 [-0.7, 3.4] 9.2 0.000 [6.6, 11.8] 8.5 0.000 [6.0, 11.0] 
3 1.0 0.359 [-1.1, 3.1] 15.3 0.000 [12.6, 18.0] 13.6 0.000 [11.0, 16.2] 
Self-rated health (Excellent)         
Very good -1.0 0.169 [-2.4, 0.4] 1.2 0.159 [-0.5, 2.9] 1.5 0.073 [-0.1, 3.1] 
Good -0.8 0.306 [-2.2, 0.7] -0.6 0.518 [-2.3, 1.2] 0.0 0.998 [-1.7, 1.7] 
Fair/Poor 0.6 0.495 [-1.1, 2.3] 2.2 0.031 [0.2, 4.2] 2.2 0.027 [0.2, 4.1] 
Health plan 
(No)          
Yes 2.1 0.07 [-0.2, 4.3] 7.8 0.000 [5.3, 10.4] 7.4 0.000 [5.0, 9.7] 
Has doctor (No)          
Yes 3.7 0.000 [1.6, 5.7] 15.3 0.000 [12.9, 17.6] 13.6 0.000 [11.4, 15.9] 
Checkup within last 30 days (No)        
Yes 8.9 0.000 [7.7, 10.0] 10.4 0.000 [9.0, 11.9] 11.5 0.000 [10.1, 12.9] 
PSA test within last 2 years (No)        
Yes 11.9 0.109 [10.9, 13.0] 20.2 0.188 [18.8, 21.7] 22.2 0.207 [20.7, 23.6] 
Physical Activity          
Yes 1.6 0.006 [0.4, 2.7] 2.8 0.000 [1.5, 4.2] 2.8 0.000 [1.5, 4.1] 
Smoker (No)          
Yes 1.5 0.038 [0.1, 2.9] -6.3 0.000 [-7.9, -4.7] -4.1 0.000 [-5.6, -2.5] 
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Table 6: Adjusted marginal changes of predicted probability of undergoing CRC screening, women, 50 - 80 years old 
  FOBT Endoscopy Either test 
Characteristic 
Marginal 
change P>z 95% CI 
Marginal 
change P>z 95% CI 
Marginal 
change P>z 95% CI 
GI density (0 - 1.3)          
1.3 - 4.2 0.9 0.090 [-0.1, 1.9] 2.7 0.000 [1.4, 4.0] 2.3 0.000 [1.1, 3.5] 
4.2 - 6.8 1.6 0.006 [0.4, 2.7] 2.5 0.001 [1.1, 3.9] 2.2 0.002 [0.8, 3.6] 
> 6.8 -0.2 0.778 [-1.5, 1.2] 3.0 0.001 [1.3, 4.7] 1.4 0.102 [-0.3, 3.0] 
PCP density (2 - 53.3)         
53.3 - 71.3 -0.5 0.441 [-1.6, 0.7] -0.9 0.206 [-2.4, 0.5] -0.7 0.317 [-2.1, 0.7] 
71.3 - 88.5 0.5 0.423 [-0.7, 1.7] -1.0 0.186 [-2.6, 0.5] -0.5 0.506 [-2.0, 1.0] 
88.5 -  113.7 1.2 0.063 [-0.1, 2.6] 0.3 0.719 [-1.3, 1.9] 1.5 0.069 [-0.1, 3.0] 
>113.7 -1.6 0.028 [-3.0, -0.2] 1.1 0.250 [-0.8, 2.9] 1.2 0.204 [-0.6, 3.0] 
Age (0 - 54)          
55 - 59 3.7 0.000 [2.6, 4.8] 15.1 0.000 [13.6, 16.6] 14.7 0.000 [13.3, 16.2] 
60 - 64 7.2 0.000 [6.0, 8.3] 19.5 0.000 [18.0, 20.9] 19.2 0.000 [17.7, 20.6] 
65 -79 8.7 0.000 [7.5, 9.9] 20.8 0.000 [19.3, 22.3] 20.6 0.000 [19.1, 22.1] 
70 - 74 10.8 0.000 [9.4, 12.2] 22.9 0.000 [21.3, 24.5] 23.0 0.000 [21.5, 24.6] 
75 - 80 10.4 0.000 [9.0, 11.9] 23.6 0.000 [21.9, 25.3] 23.8 0.000 [22.2, 25.5] 
Race (White)          
Black 5.2 0.000 [3.7, 6.7] 0.8 0.315 [-0.8, 2.4] 1.7 0.029 [0.2, 3.2] 
Hispanic 0.1 0.905 [-1.8, 2.0] -5.0 0.000 [-7.4, -2.6] -3.4 0.004 [-5.7, -1.1] 
Other 2.2 0.034 [0.2, 4.2] -6.1 0.000 [-8.5, -3.6] -4.6 0.000 [-7.0, -2.3] 
Marital status (Unmarried)         
Widowed -0.4 0.476 [-1.5, 0.7] -0.5 0.495 [-1.9, 0.9] -1.4 0.043 [-2.8, 0.0] 
Married -0.4 0.444 [-1.3, 0.6] 1.9 0.001 [0.8, 3.0] 0.9 0.092 [-0.1, 2.0] 
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Table 6. (Continued) 
  FOBT Endoscopy Either test 
Characteristic 
Marginal 
change P>z 95% CI 
Marginal 
change P>z 95% CI 
Marginal 
change P>z 95% CI 
SES          
1 0.2 0.845 [-1.4, 1.7] 2.7 0.010 [0.6, 4.8] 3.1 0.003 [1.1, 5.2] 
2 0.5 0.510 [-0.9, 1.9] 8.5 0.000 [6.6, 10.4] 8.2 0.000 [6.3, 10.0] 
3 0.6 0.426 [-0.9, 2.1] 13.1 0.000 [11.1, 15.0] 12.1 0.000 [10.2, 14.1] 
Self-rated health (Excellent)         
Very good 0.2 0.719 [-0.9, 1.3] 2.4 0.001 [1.0, 3.8] 2.0 0.002 [0.7, 3.4] 
Good -0.5 0.364 [-1.7, 0.6] 4.3 0.000 [2.9, 5.8] 3.2 0.000 [1.8, 4.6] 
Fair/Poor 0.3 0.696 [-1.1, 1.6] 8.0 0.000 [6.4, 9.6] 6.4 0.000 [4.8, 7.9] 
Health plan (No)          
Yes 1.7 0.067 [-0.1, 3.4] 8.3 0.000 [6.1, 10.5] 7.2 0.000 [5.2, 9.2] 
Has doctor (No)          
Yes 5.6 0.000 [3.6, 7.5] 13.0 0.000 [10.6, 15.4] 12.8 0.000 [10.6, 15.1] 
Checkup within last 30 days 
(No)         
Yes 6.4 0.000 [5.4, 7.4] 9.4 0.000 [8.1, 10.7] 10.1 0.000 [8.8, 11.3] 
Mammography within last 2 years (No)        
Yes 10.9 0.101 
[10.1, 
11.7] 26.8 0.255 [25.5, 28.1] 27.9 0.266 [26.6, 29.3] 
Physical Activity          
Yes 2.1 0.000 [1.2, 2.9] 2.3 0.000 [1.3, 3.4] 2.7 0.000 [1.7, 3.7] 
Smoker (No)          
Yes -1.8 0.001 [-2.9, -0.8] -7.4 s [-8.8, -6.1] -6.3 0.000 [-7.6, -5.0] 
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Table 7: Adjusted predicted marginal probability of having undergone either FOBT or 
endoscopy: Low screening participation states versus high screening participation states 
  States with low screening rates   States with high screening rates 
Characteristic 
Marginal 
change P>z 95% CI   
Marginal 
change P>z 95% CI 
GI density (0 - 1.3)        
1.3 - 4.2 3.7 0.007 [1.0, 6.4]  1.9 0.250 [-1.3, 5.0] 
4.2 - 6.8 6.3 0.000 [2.9, 9.7]  0.1 0.950 [-3.4, 3.6] 
> 6.8 8.2 0.000 [4.6, 11.8]  -1.7 0.491 [-6.6, 3.1] 
PCP density (2 - 
53.3)        
53.3 - 71.3 -2.4 0.065 [-5.0, 0.1]  -0.3 0.897 [-4.4, 3.8] 
71.3 - 88.5 1.5 0.395 [-1.9, 4.9]  4.7 0.026 [0.5, 8.8] 
88.5 - 113.7 -4.1 0.031 [-7.7, -0.4]  1.1 0.646 [-3.6, 5.7] 
>113.7 -2.1 0.389 [-7.0, 2.7]  5.2 0.040 [0.2, 10.3] 
Age (0 - 54)        
55 - 59 10.9 0.000 [7.7, 14.1]  13.1 0.000 [9.6, 16.7] 
60 - 64 16.7 0.000 [13.5, 19.9]  15.9 0.000 [12.2, 19.5] 
65 -79 17.8 0.000 [14.4, 21.1]  17.2 0.000 [13.6, 20.8] 
70 - 74 17.7 0.000 [14.2, 21.2]  19.9 0.000 [16.0, 23.8] 
75 - 80 19.3 0.000 [15.4, 23.1]  20.0 0.000 [15.8, 24.2] 
Race (White)        
Black -1.9 0.177 [-4.6, 0.9]  2.2 0.209 [-1.3, 5.8] 
Hispanic -7.7 0.016 [-14.0, -1.4]  -6.8 0.264 [-18.8, 5.2] 
Other 1.5 0.494 [-2.9, 5.9]  -8.8 0.040 [-17.2, -0.4] 
Marital status (Unmarried)       
Widowed 2.4 0.142 [-0.8, 5.5]  -0.7 0.720 [-4.8, 3.3] 
Married 2.9 0.021 [0.4, 5.4]  3.6 0.007 [1.0, 6.2] 
SES        
1 3.5 0.060 [-0.1, 7.1]  5.3 0.087 [-0.8, 11.4] 
2 8.0 0.000 [4.8, 11.3]  8.5 0.002 [3.1, 14.0] 
3 12.0 0.000 [8.4, 15.6]  12.1 0.000 [6.3, 17.8] 
Self-rated health (Excellent)       
Very good 0.5 0.777 [-2.8, 3.7]  3.0 0.098 [-0.6, 6.6] 
Good 2.9 0.075 [-0.3, 6.1]  5.7 0.003 [2.0, 9.5] 
Fair/Poor 6.1 0.000 [2.8, 9.5]  9.4 0.000 [5.2, 13.6] 
Health plan (No)        
Yes 6.2 0.001 [2.6, 9.9]  4.2 0.092 [-0.7, 9.1] 
Has doctor        
No 11.9 0.000 [8.1, 15.6]  7.0 0.002 [2.5, 11.5] 
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Table 8. (Continued) 
  States with low screening rates   States with high screening rates 
Characteristic 
Marginal 
change P>z 95% CI   
Marginal 
change P>z 95% CI 
Checkup in last 30 days (No)       
Yes 13.4 
0.00
0 [10.7, 16.0]  12.3 
0.00
0 [9.0, 15.6] 
PSA or Mammography (No)       
Yes 26.3 
0.23
7 [23.7, 28.9]  22.6 
0.19
2 [19.2, 26.0] 
Physical Activity        
Yes 0.8 
0.42
8 [-1.2, 2.9]  4.8 
0.00
0 [2.2, 7.4] 
Smoker (No)        
Yes -5.3 
0.00
0 [-8.0, -2.6]  -6.1 
0.00
1 [-9.7, -2.4] 
Gender (Female)        
Male 3.1 
0.00
2 [1.1, 5.1]   4.8 
0.00
0 [2.4, 7.2] 
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Chapter 5: Effect of state-mandated colorectal cancer screening benefits 
on screening participation 
INTRODUCTION 
Colorectal cancer (CRC) is the second leading cause of death among 
cancers that affect both men and women138.  There has been mounting evidence 
over the past 20 years that screening can reduce CRC incidence and mortality 
10,106,108–111,139,140.  Between 1998 and 2010 several states passed laws or 
arranged agreements with health insurance organizations to offer coverage for 
CRC screening141.  States historically have used legislation to require health 
insurers to cover specific services or providers.  These so-called mandated 
benefits may include coverage for specific health conditions and preventive 
services, the availability of specific professionals and coverage for certain 
populations61,64.  Early adopters of CRC coverage mandates included California, 
Illinois, Minnesota and Missouri.  The mandates and agreements established by 
states had varying scopes.  Some states required a complete coverage of CRC 
screening based on the CRC screening guidelines from the American Cancer 
Society while others were not explicit on the extent of coverage.  By 2010, a total 
of 35 states, including the District of Columbia had some form of mandated CRC 
screening coverage. 
The positive correlation between having health care insurance and CRC 
screening is well-established44,124,142.  However, the question of the effectiveness 
of mandates is specific to the extent of the benefits under a particular health care 
insurance.  Empirical evidence about the effectiveness of state-mandated health 
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insurance benefits for colorectal cancer screening is limited.  The only study that 
examined the association between mandates and CRC test use found a small 
positive correlation71.  Two studies found that among those insured under 
Medicare, the extent of the covered benefits impacted the use of CRC tests143,144.  
Of the Medicare populations included in both studies, those who had better 
coverage were significantly more likely to obtain CRC screening. 
In this paper, we use four waves of cross-sectional survey data to 
investigate the effectiveness of state-mandated CRC screening coverage.  
Specifically, we estimate the effect of state-mandated CRC coverage on the 
probability of an insured individual undergoing CRC screening. 
METHODS 
Data 
The main data for our analyses were obtained by merging cross-sectional 
surveys from the Behavioral Risk Factor Survey System (BRFSS) 131.  We 
combined data from years 2002, 2004, 2006 and 2008.   We did not use surveys 
conducted before 2001 in order to avoid any confounding effects of the Medicare 
coverage of CRC screening that began in 2001.  Surveys collected after 2009 
were also excluded because of the still-evolving effects of the coverage 
mandates introduced by the Patient Protection and Affordable Care Act of 
201058.  The BRFSS provides publicly-available survey data collected annually 
through collaborations between the Centers for Disease Control and Prevention 
(CDC) and states.  The telephone-based surveys collect data on U.S. residents 
18 years or older regarding their health-related risk behaviors, chronic health 
59 
 
conditions, and use of preventive services. Data are available for all 50 states as 
well as the District of Columbia and three U.S. territories. The BRFSS has two 
sets of questions in each particular year, namely fixed core and standard core.  
The fixed core is a standard set of questions asked by all states that includes on 
questions on demographic characteristics. The rotating core is made up of two 
distinct sets of questions, each asked in alternating years by all states, 
addressing different topics.  The questions about CRC screening use we 
employed in our analyses are part of the rotating core of question which have 
administered every even year since 2000. 
In addition to the BRFSS data we compiled data on CRC coverage 
mandates from multiple sources, including the American Cancer Society, the 
National Cancer Institute’s State Cancer Legislation Database and the National 
Council of State Legislatures (NCSL)56,57.  Our study included only states which 
have CRC coverage mandates that are backed by law and are specific in the 
coverage benefits. For the purposes of our analysis, the position of states 
regarding insurance coverage for CRC screening could be classified in one of 
three groups, namely: (1) States that had no policy on insurance coverage for 
screening, (2) States that had some voluntary arrangement with insurance 
organization or legislation to offer coverage but coverage was not required by 
law, and (3) States that had passed legislation that required insurance 
organization to provide screening coverage in their offered policies and are 
specific in the coverage benefits.  Our analysis included only states in the third 
group. 
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For each respondent in the BRFSS data, we created a variable that 
indicated the year a mandate was passed in their state of residence.  From that 
we created a new categorical variable indicating whether the respondent was 
exposed to a CRC coverage mandate or not at the time of the interview.  We 
included thirteen states had a colorectal cancer screening mandate between 
January 1, 2003 and January 1, 2008.   Within this period, Nevada passed the 
first mandate on October 10, 2003 and New Mexico passed the last mandate on 
April 1, 2007.  This ensured that each of the included states had a pre and post 
mandate period between 2002 and 2008. 
 
Variables 
CRC screening status 
The BRFSS includes a CRC module designed to elicit information about 
the CRC test use among respondents. The CRC module includes questions on 
fecal occult blood test (FOBT) and endoscopic test (sigmoidoscopy or 
colonoscopy) use.  The questions pertaining to each test included whether the 
test had been received and the time elapsed since the test was received.  For 
each individual in the BRFSS data, we calculated three binary variables 
indicating whether they were adequately screened using 1) FOBT, 2) endoscopy 
(defined as either sigmoidoscopy or colonoscopy) or 3) either FOBT or 
endoscopy.  We defined being adequately screened with FOBT as having been 
tested with FOBT within the last 2 years.  To calculate FOBT status, we used the 
following two questions from the BRFSS survey:  
61 
 
(1) A blood stool test is a test that may use a special kit at home to determine whether 
the stool contains blood.  Have you ever had this test using a home kit?; and 
(2) How long has it been since you had your last blood stool test using a home kit? 
An individual’s endoscopy status, defined as having received sigmoidoscopy or 
colonoscopy in the last 5 years, was calculated from the following three 
questions: 
(1) Sigmoidoscopy and colonoscopy are exams in which a tube is inserted in the 
rectum to view the colon for signs of cancer or other health problems. Have you ever 
had either of these exams? 
(2) For a sigmoidoscopy, a flexible tube is inserted into the rectum to look for 
problems. A colonoscopy is similar, but uses a longer tube, and you are usually given 
medication through a needle in your arm to make you sleepy and told to have 
someone else drive you home after the test. Was your most recent exam a 
sigmoidoscopy or a colonoscopy? 
(3) “How long has it been since you had your last sigmoidoscopy or colonoscopy?”  
CRC coverage mandate 
The primary predictor variable for our analyses is the whether a state had 
passed a comprehensive CRC screening coverage mandate or not at the time of 
the BRFSS survey interview.  By a comprehensive CRC screening mandate, we 
mean a mandate that specified the ACS screening guidelines as a minimum 
benefit. 
Other variables independent variables 
All individual-level analyses included demographic characteristics such as 
race, marital status, education and income level obtained from the BRFSS data. 
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We also included health care access variables and risk factor indicators where 
they were available for all four waves of data (Table 10). 
Statistical Analysis 
To test the hypothesis that individuals exposed to state-mandated CRC 
screening coverage will have a greater probability of undergoing CRC screening 
we employed a difference-in-differences (DID) logistic regression model to 
analyze cross-sectional data pooled from different years. The sample for the DID 
analysis included individuals 50-75 years old who indicated having health 
insurance and resided in states that passed a CRC screening coverage mandate 
between 2003 and 2008.  Only states that passed mandates that specified the 
American Cancer Society’s CRC screening guidelines were included. 
The DID model is commonly used to assess the impact of a policy by 
comparing the exposed (or treatment) group to those unaffected (control group) 
by the policy (Appendix 9).  One of the desirable characteristics of the DID 
method is that it the differencing technique cancels out time-invariant 
heterogeneity between the treatment and control groups. A cardinal assumption 
of the DID method is that the treatment and control groups would exhibit the 
same underlying relative trends in the absence of the policy.  This assumption is 
sometimes referred to as the parallel paths or common trends assumption.  
 
For our analyses, one choice of treatment and control groups would be 
those 50 to 64 years of age residing in CRC screening coverage mandate states 
and non-mandate states, respectively. However, using non-treatment groups 
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from non-mandates in a DD or a triple difference estimation would be an 
incorrect specification if the impetus to pass CRC screening coverage mandates 
is endogenous to the same factors that promote the screening uptake.  To 
control for the possible endogeneity of the passing of CRC screening coverage 
mandates, we use a comparison group from within the same state as the 
treatment group. 
Because Medicare coverage of CRC screening was mandated in 2001, 
we assume that policy mandates enacted for commercial plans should have no 
effect on the screening behavior of Medicare-eligible individuals. In our analysis, 
we use the Medicare eligibility age of 65 years as the cut-off point to define our 
treatment and control groups.  Specifically, we defined the control group as 
individuals 65 to 75 years old and the treatment group included those 50 to 64 
years old. The DID model allows us to separate the underlining difference 
between the treatment group (50-64 years old) and the comparison group (65-75 
years old) from the effect of the treatment (mandated CRC coverage)145,146.  The 
general form of the DID estimation is provided in Equation 1. 
Equation 1. Difference-in-difference model specification 
𝑌𝑌𝑖𝑖𝑖𝑖𝑖𝑖 = 𝐹𝐹(𝛽𝛽0 + 𝛽𝛽1𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖𝑖𝑖𝑖𝑖 + 𝛽𝛽2𝑀𝑀𝑇𝑇𝑀𝑀𝑀𝑀𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖𝑖𝑖𝑖𝑖 + 𝛽𝛽3(𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖𝑖𝑖𝑖𝑖 ×𝑀𝑀𝑇𝑇𝑀𝑀𝑀𝑀𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖𝑖𝑖𝑖𝑖) + 𝛽𝛽4𝑋𝑋𝑖𝑖𝑖𝑖𝑖𝑖 + 𝜀𝜀𝑖𝑖𝑖𝑖𝑖𝑖) 
𝑤𝑤ℎ𝑇𝑇𝑇𝑇𝑇𝑇 , 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖𝑖𝑖𝑖𝑖 = �0, if in 50-64 years old group1, if in >64 years old group  
𝑀𝑀𝑇𝑇𝑀𝑀𝑀𝑀𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖𝑖𝑖𝑖𝑖 = �0, if pre-mandate period1, if post-mandate period 
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In Equation 1, Treatijt is a binary variable indicating whether an individual 
from state j belongs to the treatment group or the comparison group.  Mandateijt 
is another binary variable indicating whether an individual, in year t of answering 
the survey, resided in a state that had passed a mandate or not.  The interaction 
binary variable Treatijt x Mandateijt indicates whether an individual in state j was 
exposed to a mandate at time t.  Xijt represents a vector of covariates; including 
dummy variables for the year the survey was conducted to capture time secular 
trends.  Yijt represents the probability of the ith individual in state j at year t 
underwent CRC screening or not.  Time-invariant state effects were captured by 
including dummy state variables.  The timing of the passage of mandates may in 
itself be serially correlated, going from one state to another. In addition, the panel 
data we used in the estimation may suffer from autocorrelation within states.  
These conditions can severely understate the standard deviation of the 
estimators. To account for intracorrelation, we estimated robust standard errors 
clustered at the state level 147. 
 
RESULTS 
Sample Characteristics 
Our analysis sample consisted of a treatment group of adults 50-64 years 
old and a control group of 65-75 year old who had health insurance and resided 
in a state that passed a comprehensive CRC screening mandate between 2003-
2008.  A total of 50,934 respondents from were obtained BRFSS data from 
seven states that passed mandates during the study period were included.  
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Approximately half (52.2%) of the respondents had been exposed to a mandate 
for at least six months at the time of their interview.  The use of FOBT declined 
between the pre-mandate and post-mandate periods (27.5% versus 21.5%).  In 
contrast, there was an increase in the use of endoscopy from 38.8% in the pre-
mandate period to 47.5% in the post-mandate period.  The proportion of 
respondents who indicated having been screened for CRC with either FOBT or 
endoscopy also increased from 51.8% to 56.4%.  The composition of race was 
similar between the pre-mandate and post-mandate periods. Whites made up 
76.9% of the total sample.  Of the remaining, 13.1% were black, 5.1% were 
Hispanic and 4.9% other race.  The distribution of the pre- and post-mandate 
marital status and educational attainment of the respondents were almost 
identical.  Income, smoking status, health status and history of mammography or 
prostate antigen specific (PSA) testing were distributed similarly in the pre- and 
post-mandate groups.  We included a “refused” category for the income variable 
because it comprised 9.7% and 8.9% of the pre- and post-mandate groups, 
respectively. 
Adjusted probabilities of having undergone CRC screening 
To examine the effect of state-mandated CRC screening coverage on 
CRC screening participation, we performed several logistic models with state and 
time fixed effects.  An initial model on the entire sample did not produce a 
significant mandate effect.  In order to account for the separate effect of a 
respondent’s mammography status and PSA testing status for women and men, 
respectively, we ran two independent models.  Tables 11 and 12 show the odds 
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ratios and predicted marginal probabilities for separate models of women and 
men.  The treatment group, represented by those 50-64 years old, was 11.62% 
and 15.2% points less likely to have undergone screening compared to those 65-
75 years old for men and women, respectively.  The largest effect detected in our 
model was associated with an individual’s history of other screening tests. 
Among women, having had mammography within the previous two years 
resulted in absolute increase of 26.3% in the probability of having undergone 
CRC screening.  A PSA test within the previous two years resulted in an absolute 
increase of 22.2% among men.  The effects of education and income exhibited a 
trend found in other studies, with higher education attainment and income 
associated with a higher probability of having undergone CRC screening 
44,60,124,142.  Behavioral risk factor of physical exercise and smoking status were 
significantly associated with the probability of having undergone CRC screening.  
CRC screening participation increased steadily from 2002 to 2008 by an absolute 
value of 1.3% to 6.9%.  This trend is consistent with several studies 38,44,124,142. 
The effect of state-mandated CRC screening coverage 
The coefficient of Age50-64*Mandate represents the effect of mandated 
CRC screening coverage on the 50-64 years old group.  No statistically 
significant effect was observed for mandates and undergoing screening with any 
test for either men or women.  However, we found a mandate effect when we ran 
separate models that compared up-to-date screening with endoscopy versus 
otherwise (Tables 13 and 14). We observed a 0.6% (p=0.055) point increase in 
the probability of undergoing endoscopy among insured men who were exposed 
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to mandates.  Among women, we did not a find a statistically significant effect of 
mandates on the insured 50-64 years old group.  (See Appendix 11 and 
Appendix 12 for full model results). Our models with FOBT status as the outcome 
variable did not yield any significant results for men or women (Appendix 13 - 
Appendix 14). 
DISCUSSION 
We compared insured 50-64 year old persons to those 65-75 years old in 
states that passed CRC screening mandates between 2003 and 2008.  In 
separate analyses for men and women we observed no significant change in the 
probability of having been screened with only FOBT or only endoscopy.  The 
analyses for men did not yield any significant effect attributable to state-
mandated CRC screening coverage.  We found a small but significant increase in 
CRC screening participation among insured women who resided in states with 
CRC screening mandates.   
To account for the possibility that effect of mandates, in terms of 
dissemination and subsequent change in beneficiaries’ behavior, required time to 
manifest we examine three different specifications of the start of the post-
mandate period. First we considered a post-mandate period that started 
immediately after the mandate went to effect.  We then considered lags of six 
months and one year after a mandate went into effect to before the post-mandate 
period started.  In all cases our conclusions did not change significantly. 
Several reasons could account for the small magnitude of the effect.  
Primary among them is the Employee Retirement Security Act (ERISA) effect.  
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ERISA limited the power states had to regulate employee-provided health plans.  
As a result, an unknown but sizable proportion of the sample was exempt from 
mandates.  An analysis of a subpopulation not exempt from the effect of 
coverage mandate may produce a different result.  Another important 
consideration is the underlying factors influencing the enactment of mandated 
benefits.  It is plausible that for states that mandated CRC screening coverage 
the impetus for passing the mandate also correlated with the other factors that 
were associated with screening uptake in the state.  In other words, the 
motivation to pass the mandate was not necessarily borne out of an empirically 
determined need to provide CRC screening access. This potentially poses an 
endogeneity problem148, in which case other estimation techniques have to be 
considered. 
Theory and evidence suggest that mandated insurance benefits have both 
negative and positive consequences.  For example, a mandated CRC screening 
benefit could increase utilization of CRC screening without increasing 
participation by facilitating repeated use among individuals who would undergo 
limited testing without the mandate.  If a mandate has the undesirable effect of 
discouraging employers from offering some health insurance or pricing out 
individuals, then at the societal level, any gains derived from mandating coverage 
could be eroded by fewer individuals having access to health insurance.    
STUDY LIMITATIONS 
Our study has some limitations.  First, and most importantly, ERISA 
exempts firms that self-insure from state insurance mandates61 .  With the 
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BRFSS data, it was not feasible to distinguish between ERISA-exempt 
individuals from those not exempt.  The likely effect of this is that we may have 
mischaracterized individuals as having benefited from state mandates and 
consequently diluting the true effect of mandates.  Second, by considering only 
states which had passed a mandate in the study period our analysis considered, 
we were unable to isolate effects that were common to mandate and non-
mandate states. As a result, our analyses could be biased by disturbances that 
were not isolated to mandates.  Third, our use of respondents 65-75 years old as 
a control group may not be appropriate.  Other policies or factors outside of the 
state mandated coverage of CRC could have impacted the control group but not 
the treatment group.  The alternative of using an equivalent age group of those 
50-64 years old in non-mandate states has some challenges as well. In the 
alternative specification, systematic differences in the screening behaviors 
between the treatment states and control states will bias the analysis.  Fourth, we 
could not separate CRC tests performed for solely for screening from those 
performed for diagnostic purposes. Thus, it was not possible to isolate the effects 
of predictors on screening colonoscopies only.  However, it is unlikely that our 
analysis was substantially confounded since screening colonoscopies comprise a 
much greater proportion of all colonoscopies in the cohorts.  Fifth, the BRFSS 
data are self-reported and may suffer from responder bias. Respondents may 
have inaccurately reported the time of their last CRC screening.  The effect of 
such a systematic recall bias would be to generate a greater mandate effect. 
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CONCLUSION 
Our study found that state mandated CRC screening coverage has a 
significant but small effect on the probability of insured women undergoing CRC 
screening.  
The effect of health insurance coverage on utilization of CRC screening 
tests may operate at three levels, namely:  (1) through physician 
recommendation by providing access to primary care; (2) whether the benefits 
under that insurance plan cover CRC screening; and (3) the level of cost-sharing 
embedded in the benefits. Our study was able to examine only the effect 
mandates operating at level two above.  Further work is needed to understand 
fully the impact of state-mandated CRC screening benefits. 
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Table 8: States with comprehensive CRC screening coverage mandates, 2003-2007 
State Effective date of mandate 
Nevada 10-Oct-03 
Illinois 1-Jan-04 
Arkansas 1-Aug-05 
Oregon 23-Aug-05 
Louisiana 1-Jan-06 
Alaska 1-Jan-07 
New Mexico 1-Apr-07 
 
  
72 
 
Table 9: Characteristics of analysis sample: U.S. adults aged 50-75 years with health insurance 
and reside in states with mandated CRC screening coverage, 2002-2008 
  Pre-mandate Post-mandate 
Charateristic N % N % 
Total 69092 22.1 151498 77.9 
FOBT 20184 30.1 38097 25.2 
Endoscopy 31541 42.7 77786 49.5 
FOBT or endoscopy 39500 55.7 91214 58.9 
Gender (Female) 41750 52.6 92928 52.4 
Age group (50 - 64 yr / 65 - 75 yr) 44411 66.9 95814 68.8 
Race     
White 58031 80.2 123273 73.6 
Black 3454 9.1 14482 9.3 
Hispanic 3356 5.6 6408 10.7 
Other 3555 5.1 5769 6.5 
Marital status     
Married 42532 72.0 89924 71.0 
Widowed 22695 24.0 50964 24.1 
Never married 3608 4.0 10089 4.9 
Education     
Less than high school 5743 10.3 15163 11.0 
Graduated high school 18631 28.8 45262 26.5 
Some college 19804 26.2 31637 25.6 
Graduated college 24761 34.7 53526 36.9 
Income     
less than $20,000 9264 13.0 22356 14.2 
less than $35,000 14277 19.9 26310 16.5 
less than $75,000 21926 33.2 43617 30.4 
greater than $75,000 14144 23.6 37474 30.2 
Refused 6219 10.4 14306 8.8 
Smoker     
Current smoker 10980 16.9 24295 14.9 
Former smoker 25621 36.9 55679 36.3 
Never smoked 32177 46.3 70987 48.8 
Excellent/Good Health (No/Yes) 14143 21.5 117795 21.5 
Has doctor/usual place of care (No/Yes) 6096 8.3 10291 8.1 
Physical activity in last 30 days (No/Yes) 16256 25.5 40848 25.7 
Mammography in last 2 years (No/Yes) 5354 12.7 11125 12.5 
PSA in last 2 years (No/Yes) 2552 11.8 4721 11.5 
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Table 10: Odds ratio and adjusted marginal changes of predicted probability of undergoing 
colorectal cancer screening with either FOBT or endoscopy for men 
 
Odds 
Ratio P>z 95% CI 
Marginal 
change 
Age 50-64 years (No)     
Yes 0.51 0.000 (0.49, 0.53) -11.6% 
Mandate (No)     
Yes 0.93 0.125 (0.84, 1.02) -0.1% 
Age 50-64 * Mandate (No)     
Yes 1.00 0.956 (0.95, 1.06) 2.8% 
Race (White)     
Black 1.01 0.788 (0.93, 1.1) 5.3% 
Hispanic 1.00 0.953 (0.88, 1.13) -2.2% 
Other 0.96 0.699 (0.8, 1.16) 5.7% 
Having a doctor (Yes)     
No 2.03 0.000 (1.53, 2.68) 13.1% 
Education     
Graduated high school 1.17 0.000 (1.07, 1.27) 5.8% 
Some college 1.24 0.000 (1.2, 1.28) 9.5% 
Graduated college 1.33 0.000 (1.25, 1.41) 13.1% 
Excellent/Good health (No)     
Yes 0.81 0.000 (0.73, 0.9) -1.6% 
Income (less than $20,000)     
less than $35,000 0.99 0.686 (0.92, 1.06) -2.7% 
less than $75,000 1.15 0.012 (1.03, 1.29) 0.2% 
greater than $75,000 1.23 0.006 (1.06, 1.41) 1.4% 
Refused to answer 1.19 0.004 (1.06, 1.33) -0.4% 
Smoker (Current)     
Former 0.84 0.000 (0.78, 0.91) -2.3% 
Never 1.24 0.000 (1.17, 1.31) 5.1% 
Exercise in last 30 days (No)     
Yes 1.14 0.003 (1.04, 1.23) 1.2% 
PSA in last 2 yrs (No) 3.09 0.000 (2.49, 3.83) 22.2% 
Yes     
Year (2002)     
2004 1.07 0.555 (0.86, 1.33) 1.3% 
2006 1.37 0.000 (1.26, 1.49) 1.9% 
2008 1.34 0.004 (1.1, 1.63) 6.9% 
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Table 11: Odds ratio and adjusted marginal changes of predicted probability of undergoing 
colorectal cancer screening with either FOBT or endoscopy for women 
 
Odds 
Ratio P>z 95% CI 
Marginal 
change 
Age 50-64 years (No)     
Yes 0.57 0.000 (0.5, 0.67) -15.2% 
Mandate (No)     
Yes 1.00 0.927 (0.94, 1.06) -1.7% 
Age 50-64 * Mandate (No)     
Yes 1.14 0.120 (0.97, 1.34) 0.0% 
Race (White)     
Black 1.29 0.000 (1.2, 1.39) 0.3% 
Hispanic 0.91 0.001 (0.85, 0.96) -0.1% 
Other 1.32 0.131 (0.92, 1.88) -0.8% 
Having a doctor (Yes)     
No 1.85 0.000 (1.55, 2.22) 16.0% 
Education     
Graduated high school 1.29 0.000 (1.16, 1.43) 3.6% 
Some college 1.53 0.000 (1.39, 1.68) 4.9% 
Graduated college 1.81 0.000 (1.68, 1.96) 6.5% 
Excellent/Good health (No)     
Yes 0.93 0.045 (0.86, 1) -4.8% 
Income (less than $20,000)     
less than $35,000 0.88 0.127 (0.75, 1.04) -0.3% 
less than $75,000 1.01 0.859 (0.93, 1.1) 3.2% 
greater than $75,000 1.07 0.443 (0.91, 1.25) 4.6% 
Refused to answer 0.98 0.853 (0.79, 1.21) 3.9% 
Smoker (Current)     
Former 0.90 0.232 (0.76, 1.07) -4.0% 
Never 1.27 0.003 (1.09, 1.48) 4.9% 
Exercise in last 30 days (No)     
Yes 1.06 0.149 (0.98, 1.14) 2.9% 
Mammography last 2 yrs (No) 2.60 0.000 (2.2, 3.08) 26.3% 
Yes     
Year (2002)     
2004 1.06 0.007 (1.02, 1.11) 1.5% 
2006 1.09 0.250 (0.94, 1.26) 7.1% 
2008 1.38 0.000 (1.16, 1.65) 6.7% 
 
  
75 
 
Table 12: Marginal change of undergoing screening with endoscopy among men 
  
Marginal 
change P>z 95% CI 
Age 50-64 years (No)    
Yes -13.9% 0.000 (-16.8%, -10.9%) 
Mandate (No)    
Yes -0.9% 0.467 (-5.4%, 3.6%) 
Age 50-64 * Mandate (No)    
Yes 0.6% 0.055 (-3.1%, 4.4%) 
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 Table 13: Marginal change of undergoing screening with endoscopy among women 
 
  
Marginal 
change P>z 95% CI 
Age 50-64 years (No)    
Yes -12.5% 0.000 (-16.2%, -8.7%) 
Mandate (No)    
Yes -0.8% 0.446 (-6.6%, 5.1%) 
Age 50-64 * Mandate (No)    
Yes 3.7% 0.162 (-1.5%, 8.9%) 
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Chapter 6: Conclusions and Future implications 
This dissertation investigated the effects of colorectal cancer (CRC) over-
surveillance, county-level physician distribution and state-mandated health 
benefits on screening rates.  Very little is known about the current or future 
capacity to deliver CRC screening at sustained high participation rates.  In the 
first paper, we applied a Markov simulation model to estimate the annual demand 
for colonoscopies at various levels of screening uptake.  We explicitly modeled 
the impact of aggressive surveillance on the annual volume of colonoscopies.  
Our findings show that aggressive surveillance adds a substantial number of 
colonoscopies with little benefit.  Aggressive surveillance may accrue marginal 
benefits at the expense of increased probability of adverse outcomes.  
Additionally, in a system where gastroenterologist capacity is constrained, each 
unneeded surveillance colonoscopy is a test that could have gone to an 
unscreened person. 
Even if the available per capita gastroenterologist indicates adequate 
capacity to accommodate higher screening rates, geographic distribution and 
access barriers can still prove to be significant barriers to realizing targets.  There 
also is some evidence that physician geographic distribution can impact 
screening disparities 53,149.  In our second paper, we combined a nation-wide 
representative survey data and a physician registry to investigate the relationship 
between county-level physician supply and up-to-date CRC screening use.  
Considerable variation in county-level physician supply exists among US states.  
Our analysis found that the physician supply at the county level significantly 
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impacted the probability of an individual undergoing colonoscopy after other 
covariates were controlled for.  This effect was more acute among males than 
females.   
In the third paper we used longitudinal survey data to assess the impact of 
state-mandated CRC screening coverage on up-to-date screening rates.  In our 
analysis of seven states that enacted mandates between 2003 and 2007 we did 
not find a statistically significant effect of mandates on screening rates.  The 
absence of a significant effect of health insurance coverage mandates on 
screening rates is not entirely surprising.  Several studies have found that among 
other factors, physician recommendation and socio-economic status are major 
predictors of CRC screening status.  The strong correlation positive between 
county-level gastroenterologist density and endoscopic screening suggest that 
any positive effect of the health insurance coverage mandate may be blunted if 
the screening capacity and demand are geographically misaligned.  Such a 
situation can induce overuse of screening tests among beneficiaries of the 
mandate.   
We have shown that health insurance coverage of CRC screening tests 
does not necessarily translate into an expanded use.  They may in fact be 
counter-productive67.  A mandated benefit is of little use if there is no accessible 
gastroenterologist to provide that benefit.  The association between county-level 
physician density and the probability of being up-to-date with CRC screening 
after controlling for person-level characteristics suggests that a sustainable 
solution to eliminating disparities should consider strategies that increase the 
79 
 
number of physicians in underserved areas.  The challenge of addressing 
physician shortage in underserved areas is made even more formidable by a 
general shortage of physicians across the US150,151.  One of the consequences of 
this shortage is that there is excess demand for physicians in urban and more 
attractive areas to the extent that no economic incentive exists for physicians to 
practice in acutely underserved areas.  Several programs have therefore been 
developed at both the federal and state levels to provide incentives to physicians 
to serve in otherwise unattractive areas152.  
States offer student loan repayment programs for physicians who elect to 
serve in shortage areas.  The federal government offers a similar program for 
physicians who serve at least 2 years in shortage areas through the National 
Health Service Corps153.  Other incentives provided by states include income tax 
credits and J-1 visa waivers.  J-1 visa waivers allow foreign medical graduates to 
avoid going back to their home countries for at least two years before they are 
allowed to work in the US in exchange of working in a shortage area.  These 
programs have had some success in attracting and retaining primary care 
physicians in rural and underserved areas153. While most of the incentive 
programs are for primary/family physicians, notably, colonoscopies are mostly 
performed by gastroenterologists or colorectal surgeons154.  The precipitous shift 
from FOBT to colonoscopy as the primary screening test means increasing the 
availability of primary care physicians may have only a limited impact on CRC 
screening rates. Some have called for the training PCPs and nurse practitioners 
to perform colonoscopies20,155,156 as a way of addressing the inadequate number 
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of gastroenterologists and colorectal surgeons. In addition, it may be useful to 
use the physician incentive programs to carefully target gastroenterologists and 
colorectal surgeons to areas of need. 
In our first paper, we found that up to one million excess colonoscopies 
could be performed annually if CRC surveillance is done more frequently than 
guidelines stipulate.  Fewer unneeded surveillance colonoscopies would be 
performed if physicians adhered to guidelines and thereby freeing up 
colonoscopies for those who need them. However, several factors combine to 
prevent physicians from following guidelines.  First, the lack of a singular gold 
standard recommendation means that physicians may be exposed to 
inconsistent messages regarding what the appropriate guidelines are.  Even 
though the several recommendations issued by the USPSTF and various 
physician bodies do not differ significantly, the plurality can cause confusion.  In 
recognition of the problem, recent recommendations have being issued by joint 
committees of stakeholder physician bodies18,21.  Second, physicians have also 
exhibited a lack of knowledge of the details of guidelines within the 
recommendations157.  Several recommendations with their frequent updates 
make it even more difficult for physicians to assimilate the guidelines.  To 
overcome the problem would require more education for both physicians and the 
public on a singular baseline screening and surveillance guidelines. A gold 
standard recommendation notwithstanding, physicians still retain their autonomy 
in the delivery of care and could justify premature surveillance.  Third, there is 
little incentive in a fee-for-service payment system for a physician to defer a 
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surveillance colonoscopy for a patient when confronted with ambiguity.  The 
perverse incentive of fee-for-service payment system to reward even 
unnecessary interventions is problem that requires a health system-wide 
solution. 
Further research 
The Patient Protection and Affordable Care Act is expected to expand 
healthcare coverage to millions of previously uninsured Americans.  This influx of 
newly-insured patients is likely to put considerable strain on all healthcare 
resources. It is therefore imperative to reduce overuse of colonoscopy and gain a 
better understanding of the determinants of screening participation.  While 
programs that target underserved populations are important, they are not the 
panacea for systematic shortages or structural distributional problems associated 
with physician supply.  It is important to understand how geographic differences 
in physician supply affect screening rates and whether shortages impact the 
quality of colonoscopy. 
Legislative mandates have been used extensively by states to ensure the 
availability of certain health care services.  However, the effectiveness of 
mandates in improving screening rates is yet to be proven.  Because these 
mandates have the potential of causing undesirable effects such as test overuse 
and increase the overall cost of insurance, it is important that more research is 
conducted to expand our understanding of the policy. As a policy tool, an 
important question about mandates that needs to be carefully weighed is whether 
the societal benefits they produce outweigh the costs. 
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Appendices 
Appendix 1: Summarized CRC Screening guidelines: American Cancer 
Society, US Multi Society Task Force on CRC, American College of 
Radiology 
 
 Test  Interval  
Flexible Sigmoidoscopy  Every 5 years 
Colonoscopy Every 10 years 
Double Contrast Barium Enema  Every 5 years 
Computed Tomographic Colonoscopy Every 5 years 
gFOBT high sensitivity  Annual  
FIT high sensitivity  Annual  
 
Appendix 2: Comparison of screening rates of various recommended 
screening tests, 1999 - 2010 
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Appendix 3: Distribution of county-level primary care physicians per 
100,000 adults 
 
 
 
Appendix 4: Box plot of county-level primary care physician density at 
quintiles 
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Appendix 5: Distribution of county-level gastroenterologists per 100,000 
adults 
 
 
Appendix 6: Box plot of county-level gastroenterologist density at quartiles 
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Appendix 7: Proportion of the population up-to-date with FOBT and 
endoscopy test at quartiles of county-level gastroenterologist density  
 
Appendix 8: Proportion of the population up-to-date with endoscopy and 
FOBT at quintiles of county-level primary care physician density 
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Appendix 9: Deriving the policy effect coefficient in the difference-in-
difference model 
 
𝑌𝑌𝑖𝑖𝑖𝑖𝑖𝑖 = 𝛽𝛽0 + 𝛽𝛽1𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖 + 𝛽𝛽2𝑀𝑀𝑇𝑇𝑀𝑀𝑀𝑀𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖 + 𝛽𝛽3(𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖 × 𝑀𝑀𝑇𝑇𝑀𝑀𝑀𝑀𝑇𝑇𝑇𝑇𝑇𝑇𝑖𝑖) 
1. 𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖𝑖𝑖�𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 = 0,𝑀𝑀𝑇𝑇𝑀𝑀𝑀𝑀𝑇𝑇𝑇𝑇𝑇𝑇 = 0� = 𝛽𝛽0 
2. 𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖𝑖𝑖�𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 = 0,𝑀𝑀𝑇𝑇𝑀𝑀𝑀𝑀𝑇𝑇𝑇𝑇𝑇𝑇 = 1� = 𝛽𝛽0 + 𝛽𝛽2 
3. 𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖𝑖𝑖�𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 = 1,𝑀𝑀𝑇𝑇𝑀𝑀𝑀𝑀𝑇𝑇𝑇𝑇𝑇𝑇 = 0� = 𝛽𝛽0 + 𝛽𝛽1 
4. 𝐸𝐸�𝑌𝑌𝑖𝑖𝑖𝑖𝑖𝑖�𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 = 1,𝑀𝑀𝑇𝑇𝑀𝑀𝑀𝑀𝑇𝑇𝑇𝑇𝑇𝑇 = 1� = 𝛽𝛽0 + 𝛽𝛽1 + 𝛽𝛽2 + 𝛽𝛽3 
Difference 1 (Equation 2 – Equation 1): 𝛽𝛽0 + 𝛽𝛽2 − 𝛽𝛽0 = 𝛽𝛽2 
Difference 2 (Equation 4 – Equation 3): 𝛽𝛽0 + 𝛽𝛽1 + 𝛽𝛽2 + 𝛽𝛽3 − (𝛽𝛽0 + 𝛽𝛽1) = 𝛽𝛽2 + 𝛽𝛽3 
Difference in difference: 𝛽𝛽2 + 𝛽𝛽3 − 𝛽𝛽2 = 𝛽𝛽3  
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Appendix 10: Adjusted probability of being up-to-date with CRC screening. 
Margins from PCP-Gastroenterologist interaction 
  dy/dx Std. Err. t P>t 
[95% 
Conf. Interval] 
2.PCP_quint       
GI_quart       
1 -0.004 0.006 -0.69 0.490 -0.016 0.008 
2 -0.004 0.006 -0.69 0.489 -0.015 0.007 
3 -0.004 0.006 -0.69 0.489 -0.015 0.007 
4 -0.004 0.006 -0.69 0.489 -0.015 0.007 
3.PCP_quint             
GI_quart       
1 0.000 0.006 0.04 0.97 -0.012 0.013 
2 0.000 0.006 0.04 0.97 -0.012 0.012 
3 0.000 0.006 0.04 0.97 -0.012 0.012 
4 0.000 0.006 0.04 0.97 -0.012 0.012 
4.PCP_quint       
GI_quart       
1 0.021 0.007 3.12 0.002 0.008 0.034 
2 0.020 0.007 3.11 0.002 0.007 0.033 
3 0.020 0.007 3.09 0.002 0.007 0.033 
4 0.020 0.007 3.09 0.002 0.007 0.033 
5.PCP_quint             
GI_quart       
1 0.022 0.008 2.83 0.005 0.007 0.037 
2 0.021 0.008 2.82 0.005 0.007 0.036 
3 0.021 0.008 2.81 0.005 0.006 0.036 
4 0.021 0.008 2.79 0.005 0.006 0.036 
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Appendix 11: Output from Stata® showing the odds ratios of being up-to-
date with endoscopic screening among men only 
Endo50_75 
Odds 
Ratio Std. Err. z P>z 95% Confidence Interval 
       
1.Age50_64 0.5847 0.0400 -7.85 0.000 0.5114 0.6686 
1.Mandate1 0.9694 0.0415 -0.73 0.467 0.8914 1.0541 
1.AgeManda~1 1.1720 0.0968 1.92 0.055 0.9967 1.3780 
Race4grp       
2 1.2431 0.0474 5.71 0.000 1.1536 1.3396 
3 0.9670 0.0381 -0.85 0.394 0.8952 1.0446 
4 1.1709 0.2795 0.66 0.509 0.7334 1.8695 
       
Hasdoc 1.7719 0.1175 8.63 0.000 1.5559 2.0179 
Edu       
2 1.1306 0.0470 2.95 0.003 1.0421 1.2265 
3 1.3315 0.0309 12.32 0.000 1.2722 1.3935 
4 1.6602 0.0444 18.93 0.000 1.5753 1.7496 
       
1.Genhealth 0.9825 0.0452 -0.38 0.701 0.8977 1.0753 
Income2       
1 0.9904 0.0571 -0.17 0.867 0.8845 1.1089 
2 1.2856 0.1136 2.84 0.004 1.0812 1.5286 
3 1.3217 0.0826 4.46 0.000 1.1693 1.4939 
4 1.3122 0.1198 2.98 0.003 1.0973 1.5694 
Smoker       
1 0.8042 0.0626 -2.8 0.005 0.6904 0.9367 
2 1.2434 0.0901 3 0.003 1.0787 1.4332 
       
1.Physical 1.0224 0.0260 0.87 0.384 0.9726 1.0747 
1.Psa 1.8388 0.1077 10.4 0.000 1.6394 2.0624 
iYear2       
2004 1.1035 0.0547 1.99 0.047 1.0013 1.2161 
2006 1.3787 0.0796 5.56 0.000 1.2311 1.5440 
2008 1.7968 0.1496 7.04 0.000 1.5262 2.1154 
_state       
5 0.6788 0.0178 -14.8 0.000 0.6449 0.7146 
17 0.6666 0.0242 -11.17 0.000 0.6208 0.7157 
22 0.6562 0.0194 -14.27 0.000 0.6193 0.6952 
32 0.6982 0.0126 -19.87 0.000 0.6738 0.7233 
35 0.8190 0.0188 -8.71 0.000 0.7830 0.8566 
41 0.9330 0.0195 -3.33 0.001 0.8956 0.9719 
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Appendix 12: Output from Stata® showing the odds ratios of being up-to-
date with endoscopic screening among women only 
Endo50_75 
Odds 
Ratio Std. Err. z P>z 95% CI 
       
1.Age50_64 0.5531 0.0390 -8.41 0.000 0.4817 0.6349 
1.Mandate1 0.9610 0.0501 -0.76 0.446 0.8676 1.0645 
1.AgeManda~1 1.0270 0.0702 0.39 0.697 0.8982 1.1743 
Race4grp       
2 1.0651 0.0382 1.76 0.078 0.9929 1.1426 
3 0.9855 0.0498 -0.29 0.772 0.8925 1.0881 
4 0.9837 0.0769 -0.21 0.834 0.8440 1.1466 
       
Hasdoc 1.8723 0.2613 4.49 0.000 1.4242 2.4614 
Edu       
2 1.2039 0.0669 3.34 0.001 1.0797 1.3423 
3 1.2696 0.0355 8.52 0.000 1.2018 1.3412 
4 1.3323 0.0709 5.39 0.000 1.2004 1.4787 
       
1.Genhealth 0.8275 0.0461 -3.4 0.001 0.7419 0.9230 
Income2       
1 0.9368 0.0424 -1.44 0.149 0.8572 1.0237 
2 1.1331 0.0481 2.94 0.003 1.0426 1.2314 
3 1.2952 0.0762 4.4 0.000 1.1541 1.4535 
4 1.1525 0.0703 2.33 0.020 1.0226 1.2989 
Smoker       
1 0.8432 0.0309 -4.65 0.000 0.7848 0.9060 
2 1.2289 0.0365 6.94 0.000 1.1594 1.3025 
       
1.Physical 1.0569 0.0405 1.45 0.148 0.9805 1.1393 
1.Mam 2.7218 0.2403 11.34 0.000 2.2893 3.2361 
iYear2       
2004 1.1601 0.1026 1.68 0.093 0.9755 1.3796 
2006 1.6120 0.0594 12.95 0.000 1.4996 1.7328 
2008 1.7093 0.1350 6.79 0.000 1.4643 1.9954 
_state       
5 0.8383 0.0244 -6.06 0.000 0.7918 0.8875 
17 0.9379 0.0312 -1.93 0.054 0.8788 1.0010 
22 0.9610 0.0212 -1.8 0.071 0.9203 1.0034 
32 0.7894 0.0208 -8.98 0.000 0.7497 0.8312 
35 0.9502 0.0218 -2.22 0.026 0.9083 0.9940 
41 1.1313 0.0309 4.51 0.000 1.0723 1.1936 
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Appendix 13: Output from Stata® showing the odds ratios of being up-to-
date with FOBT among men only 
Fobt2yr 
Odds 
Ratio Std. Err. z P>z 95% Confidence Interval 
       
1.Age50_64 0.6932 0.0404 -6.29 0.000 0.6185 0.7770 
1.Mandate1 1.0455 0.0588 0.79 0.428 0.9364 1.1674 
1.AgeManda~1 1.0873 0.1011 0.9 0.368 0.9061 1.3048 
Race4grp       
2 1.3617 0.1541 2.73 0.006 1.0908 1.6999 
3 0.7093 0.0974 -2.5 0.012 0.5419 0.9284 
4 1.0739 0.1429 0.54 0.592 0.8274 1.3938 
       
Hasdoc 1.5375 0.2823 2.34 0.019 1.0728 2.2035 
Edu       
2 1.4757 0.1615 3.56 0.000 1.1908 1.8287 
3 1.5662 0.1406 5 0.000 1.3135 1.8674 
4 1.6657 0.1481 5.74 0.000 1.3994 1.9827 
       
1.Genhealth 0.9139 0.0565 -1.46 0.145 0.8097 1.0315 
Income2       
1 0.7891 0.0893 -2.09 0.036 0.6322 0.9851 
2 0.6752 0.0756 -3.51 0.000 0.5421 0.8410 
3 0.7246 0.0343 -6.8 0.000 0.6603 0.7951 
4 0.7467 0.1202 -1.81 0.070 0.5447 1.0237 
Smoker       
1 1.1342 0.0661 2.16 0.031 1.0117 1.2716 
2 1.1938 0.0302 7 0.000 1.1360 1.2546 
       
1.Physical 1.2440 0.0698 3.89 0.000 1.1145 1.3887 
1.Psa 4.2807 0.4521 13.77 0.000 3.4803 5.2651 
iYear2       
2004 0.9151 0.0212 -3.84 0.000 0.8745 0.9575 
2006 0.6040 0.1007 -3.03 0.002 0.4357 0.8373 
2008 0.5343 0.0277 -12.09 0.000 0.4827 0.5915 
_state       
5 1.4127 0.0248 19.66 0.000 1.3649 1.4623 
17 1.4568 0.0352 15.58 0.000 1.3895 1.5275 
22 1.6899 0.0524 16.92 0.000 1.5902 1.7957 
32 1.4013 0.0175 27.02 0.000 1.3674 1.4360 
35 1.6003 0.0337 22.35 0.000 1.5357 1.6677 
41 1.8717 0.0184 63.85 0.000 1.8360 1.9080 
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 Appendix 14: Output from Stata® showing the odds ratios of being up-to-
date with FOBT among women only 
Fobt2yr 
Odds 
Ratio Std. Err. z P>z 95% Confidence Interval 
       
1.Age50_64 0.5721 0.0607 -5.26 0.000 0.4647 0.7044 
1.Mandate1 0.8354 0.0821 -1.83 0.067 0.6891 1.0129 
1.AgeManda~1 1.0330 0.0787 0.43 0.669 0.8898 1.1993 
Race4grp       
2 0.9865 0.0214 -0.63 0.529 0.9455 1.0292 
3 1.0229 0.0674 0.34 0.731 0.8990 1.1638 
4 1.0147 0.1396 0.11 0.916 0.7749 1.3287 
       
Hasdoc 1.6930 0.3124 2.85 0.004 1.1792 2.4307 
Edu       
2 1.1683 0.0560 3.25 0.001 1.0636 1.2834 
3 1.2448 0.0566 4.82 0.000 1.1387 1.3608 
4 1.3111 0.0557 6.38 0.000 1.2064 1.4248 
       
1.Genhealth 0.8086 0.0243 -7.06 0.000 0.7623 0.8577 
Income2       
1 1.1707 0.1359 1.36 0.175 0.9324 1.4699 
2 1.1708 0.1113 1.66 0.097 0.9719 1.4106 
3 1.0792 0.1663 0.49 0.621 0.7979 1.4597 
4 1.2204 0.0986 2.46 0.014 1.0416 1.4298 
Smoker       
1 0.8832 0.0359 -3.06 0.002 0.8156 0.9564 
2 1.0651 0.0225 2.98 0.003 1.0219 1.1102 
       
1.Physical 1.1349 0.0703 2.04 0.041 1.0052 1.2813 
1.Mam 2.4100 0.4894 4.33 0.000 1.6187 3.5880 
iYear2       
2004 0.9073 0.0840 -1.05 0.293 0.7568 1.0877 
2006 0.7911 0.0601 -3.08 0.002 0.6816 0.9181 
2008 0.6658 0.0801 -3.38 0.001 0.5259 0.8429 
_state       
5 0.9311 0.0193 -3.44 0.001 0.8940 0.9698 
17 0.9204 0.0347 -2.2 0.028 0.8548 0.9910 
22 1.2354 0.0313 8.35 0.000 1.1756 1.2983 
32 1.1557 0.0291 5.76 0.000 1.1001 1.2141 
35 0.9701 0.0257 -1.14 0.253 0.9210 1.0219 
41 1.4503 0.0347 15.54 0.000 1.3838 1.5198  
